var title_f30_34_31264="Breast MRI for evaluating extent of disease - case 1";
var content_f30_34_31264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Breast MRI for evaluating extent of disease - case 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be used to determine the extent of disease in newly diagnosed cancer patient. The figure depicts the breast MRI of a patient with a palpable mass. Core biopsy revealed invasive lobular carcinoma. Preoperative MRI revealed extensive disease spanning over 7 cm with multiple irregular areas of enhancement (A) with intermediate signal on T2-weighted sequences (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31264=[""].join("\n");
var outline_f30_34_31264=null;
var title_f30_34_31265="Patient information: Irritable bowel syndrome (The Basics)";
var content_f30_34_31265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/53/3926\">",
"         Patient information: Irritable bowel syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Irritable bowel syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/irritable-bowel-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H478968092\">",
"      <span class=\"h1\">",
"       What is irritable bowel syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Irritable bowel syndrome, or &ldquo;IBS,&rdquo; is a condition that causes belly pain and problems with bowel movements. Some people with the condition have frequent, watery bowel movements (diarrhea). Others do not have enough bowel movements (constipation). Some patients switch back and forth between diarrhea and constipation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968099\">",
"      <span class=\"h1\">",
"       What are the symptoms of IBS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stomach pain and cramps, often right after eating",
"       </li>",
"       <li>",
"        Diarrhea or constipation (some people switch back and forth between diarrhea and constipation)",
"       </li>",
"       <li>",
"        Bloating",
"       </li>",
"       <li>",
"        Gas (burping or farting)",
"       </li>",
"       <li>",
"        Feeling full too quickly when eating",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968106\">",
"      <span class=\"h1\">",
"       Is there a test for IBS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no specific test. But your doctor or nurse can figure out if you have IBS by asking you a few questions, and by running tests to make sure you do not have something other than IBS. Lots of medical conditions can cause the same symptoms as IBS. So it is important that your doctor or nurse check the other possibilities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968113\">",
"      <span class=\"h1\">",
"       What can I do to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Start a diary to keep track of what you ate each day, what you did, and how you felt. That way, you can figure out if anything you do or eat makes your symptoms better or worse.",
"       </li>",
"       <li>",
"        Stop eating foods that might be making your IBS worse. Start by giving up milk, ice cream, and other foods that have traces of milk for 2 weeks. Ask your doctor or nurse for advice on which foods can make IBS worse.",
"       </li>",
"       <li>",
"        Eat more fiber. You can do this by eating more fruits and vegetables. Or you can take fiber pills or powders. (If eating more fiber makes symptoms worse, cut back on the fiber.)",
"       </li>",
"       <li>",
"        Exercise. Do something active for 20 to 60 minutes, 3 to 5 days a week. Studies show this helps improve IBS symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968120\">",
"      <span class=\"h1\">",
"       How is IBS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Medicines can ease the symptoms of IBS. But no treatment can cure the condition. Counseling may also help with IBS, because stress and worry can make the condition worse.",
"     </p>",
"     <p>",
"      The medicines that can help with IBS symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to ease diarrhea",
"       </li>",
"       <li>",
"        Medicines to ease constipation",
"       </li>",
"       <li>",
"        Antidepressants (These medicines can help with stress and worry, but they also work by blocking pain. When used to treat IBS, they are given at a much lower dose than would normally be given to treat depression.)",
"       </li>",
"       <li>",
"        Medicines that block nerve signals going to the intestines",
"       </li>",
"       <li>",
"        Antibiotics (These medicines sometimes help with bloating, pain and diarrhea in some people.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968127\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with IBS have the condition for the rest of their life. Even so, most people find ways to improve their symptoms. The key is to keep working with your doctor or nurse until the two of you find an approach that works.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478968134\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"       Patient information: Irritable bowel syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/34/31265?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15457 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31265=[""].join("\n");
var outline_f30_34_31265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968092\">",
"      What is irritable bowel syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968099\">",
"      What are the symptoms of IBS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968106\">",
"      Is there a test for IBS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968113\">",
"      What can I do to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968120\">",
"      How is IBS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968127\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478968134\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=related_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31266="Patient information: Tetanus (The Basics)";
var content_f30_34_31266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/32/28161\">",
"         Patient information: Animal bites (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/11/43185\">",
"         Patient information: Taking care of cuts and scrapes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/15/22770\">",
"         Patient information: Animal bites (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tetanus (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tetanus-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28987357\">",
"      <span class=\"h1\">",
"       What is tetanus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tetanus is a serious infection that causes muscle stiffness and spasms. It is sometimes called &ldquo;lockjaw&rdquo; because muscle spasms can clench the jaw shut.",
"     </p>",
"     <p>",
"      Tetanus is caused by bacteria (germs) that live in the soil. They can get into your body through a cut or scrape. Most people in the United States are protected from these bacteria because they have gotten vaccines against them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987372\">",
"      <span class=\"h1\">",
"       What are the symptoms of tetanus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stiff jaw or neck muscles, which make it hard to move your jaw or neck normally",
"       </li>",
"       <li>",
"        Strange-looking smile that does not go away when you try to relax your mouth",
"       </li>",
"       <li>",
"        Tight, painful muscles that do not let go when you try to relax them",
"       </li>",
"       <li>",
"        Trouble breathing, swallowing, or both &nbsp;",
"       </li>",
"       <li>",
"        Feeling irritable or restless",
"       </li>",
"       <li>",
"        Sweating even when you are not exercising or hot",
"       </li>",
"       <li>",
"        Heartbeat that is faster than usual, or irregular heartbeat &nbsp;",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Painful muscle spasms",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who are very sick with tetanus can have muscle spasms that force the body into a &ldquo;bridge&rdquo; position. They might have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Clenched fists",
"       </li>",
"       <li>",
"        Back arched off the floor or bed",
"       </li>",
"       <li>",
"        Legs stretched out",
"       </li>",
"       <li>",
"        Arms moving back and forth",
"       </li>",
"       <li>",
"        Trouble breathing &ndash; They might even stop breathing during a muscle spasm.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with tetanus have tight muscles and muscle spasms in just 1 part of the body. For example, they might have stiff, hard belly muscles. Tetanus in the head or neck can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        Stiff jaw or neck muscles",
"       </li>",
"       <li>",
"        Severe pain in the face or head",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987387\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You get a cut, scrape, or other injury you cannot clean completely, or an injury leaves something (like a nail or glass) inside your body.",
"       </li>",
"       <li>",
"        An animal bites you and your last tetanus shot was 5 years ago or longer. You should also go if an animal bites you and you do not remember getting a tetanus shot.",
"       </li>",
"       <li>",
"        You have diabetes, and get a sore on your foot, leg, or other place.",
"       </li>",
"       <li>",
"        You have a stiff jaw or neck, other tight muscles you cannot relax, or painful muscle spasms.",
"       </li>",
"       <li>",
"        You have trouble breathing or swallowing. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987402\">",
"      <span class=\"h1\">",
"       Is there a test for tetanus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no simple test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and vaccine history, and by doing an exam. This infection is most likely in people who have had an injury and who have not had the tetanus vaccine at all or not had the right vaccine boosters.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987416\">",
"      <span class=\"h1\">",
"       Is tetanus dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with tetanus need to go to the hospital, and some people even die from it. The muscle spasms can stop your breathing. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987433\">",
"      <span class=\"h1\">",
"       How is tetanus treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat tetanus in the hospital, sometimes in the intensive care unit (ICU). Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cleaning cuts or scrapes to remove skin and tissue that could have tetanus bacteria on it",
"       </li>",
"       <li>",
"        Giving medicines to fight the infection &nbsp;",
"       </li>",
"       <li>",
"        Giving a tetanus vaccine booster",
"       </li>",
"       <li>",
"        Giving medicine and other treatments to reduce muscle spasms, breathing problems, pain, and other symptoms",
"       </li>",
"       <li>",
"        Using a ventilator (breathing machine) if you have trouble breathing on your own &nbsp;",
"       </li>",
"       <li>",
"        Using a feeding tube if you cannot eat or drink on your own",
"       </li>",
"       <li>",
"        Having physical therapy to help muscles recover",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987448\">",
"      <span class=\"h1\">",
"       Can tetanus be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce your chances of getting tetanus, do these things:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get a tetanus vaccine. This is a medicine that teaches your body how to fight tetanus. Most children growing up in the United States get this vaccine as part of their routine childhood vaccines. &nbsp;",
"       </li>",
"       <li>",
"        Get regular tetanus booster shots. Adults should get tetanus booster shots every 10 years. For bad wounds, you will need to get a tetanus booster shot if you haven&rsquo;t had one in the last 5 years. If you have a bad wound and you haven&rsquo;t received all of your tetanus vaccines or you are not sure if you have, you will need a tetanus booster shot and another shot to fight any tetanus bacteria that got in the wound. &nbsp;",
"       </li>",
"       <li>",
"        Wash cuts or scrapes with soap and water and use antibiotic ointment on them. See a doctor or nurse if you cannot get all the dirt out or cannot see all the way into the wound.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Do NOT inject illegal drugs, or at least use clean needles if you do inject drugs or anything else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28987463\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/11/43185?source=see_link\">",
"       Patient information: Taking care of cuts and scrapes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=see_link\">",
"       Patient information: Animal bites (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=see_link\">",
"       Patient information: Animal bites (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/34/31266?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83176 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31266=[""].join("\n");
var outline_f30_34_31266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987357\">",
"      What is tetanus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987372\">",
"      What are the symptoms of tetanus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987387\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987402\">",
"      Is there a test for tetanus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987416\">",
"      Is tetanus dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987433\">",
"      How is tetanus treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987448\">",
"      Can tetanus be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28987463\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=related_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31267="Lidocaine and tetracaine: Patient drug information";
var content_f30_34_31267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine and tetracaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/57/43924?source=see_link\">",
"     see \"Lidocaine and tetracaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/13/35028?source=see_link\">",
"     see \"Lidocaine and tetracaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1181967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lidocaine, tetracaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any pain during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used on the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11983 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31267=[""].join("\n");
var outline_f30_34_31267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181967\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017166\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017165\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017169\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017170\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017172\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017168\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017173\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017174\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/57/43924?source=related_link\">",
"      Lidocaine and tetracaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/13/35028?source=related_link\">",
"      Lidocaine and tetracaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31268="Transformation FL";
var content_f30_34_31268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic transformation of follicular lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper lymph node shows involvement by follicular lymphoma, while the lower node shows a diffuse pattern, due to diffuse growth of large lymphoid cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31268=[""].join("\n");
var outline_f30_34_31268=null;
var title_f30_34_31269="Pyrazinamide: Drug information";
var content_f30_34_31269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrazinamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/39/29300?source=see_link\">",
"    see \"Pyrazinamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/48/16132?source=see_link\">",
"    see \"Pyrazinamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tebrazid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tuberculosis treatment:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen. Treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; pyrazinamide is administered in the initial phase of treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Suggested dosing based on lean body weight (Blumberg, 2003; CDC, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Daily therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 1500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 2000 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Twice weekly directly observed therapy (DOT):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 3000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 4000 mg (maximum dose regardless of weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Three times/week DOT:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-55 kg: 1500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     56-75 kg: 2500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-90 kg: 3000 mg (maximum dose regardless of weight)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/48/16132?source=see_link\">",
"      see \"Pyrazinamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tuberculosis treatment:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Used as part of a multidrug regimen. Treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; pyrazinamide is administered in the initial phase of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      HIV negative (CDC, 2003):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily therapy: 15-30 mg/kg/day (maximum: 2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twice weekly directly observed therapy (DOT): 50 mg/kg/dose (maximum: 2 g/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-infected:",
"     </i>",
"     Daily therapy: 20-40 mg/kg/dose once daily (maximum: 2 g/day) (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F215777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or receiving hemodialysis: Treatment of TB: 25-35 mg/kg/dose 3 times per week administered after dialysis (Blumberg, 2003; CDC, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of tuberculosis in combination with other antituberculosis agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acne, angioedema (rare), anticoagulant effect, dysuria, fever, gout, hepatotoxicity,  interstitial nephritis, itching, photosensitivity, porphyria, rash, sideroblastic anemia, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Dose-related hepatotoxicity ranging from transient ALT/AST elevations to jaundice, hepatitis and/or liver atrophy (rare) has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcoholism: Due to concerns for pre-existing hepatic dysfunction, use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: May inhibit uric acid excretion; acute gouty attacks have been reported. Use with caution in patients with chronic gout; contraindicated with acute gout.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxic agents: Use with caution in patients receiving concurrent medications associated with hepatotoxicity (particularly with rifampin).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Pyrazinamide may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: Pyrazinamide may enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13375012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Although not recommended as the initial treatment regimen, the use of pyrazinamide during pregnancy is recommended by The World Health Organization (Blumberg, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13375013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of pyrazinamide have been detected in breast milk; concentrations are less than maternal plasma concentration (Holdiness, 1984). The amount of drug in breast milk is considered insufficient for the treatment of tuberculosis in breast-fed infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F215761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pyrazinamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $142.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F215750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, serum uric acid, sputum culture, chest x-ray 2-3 months into treatment and at completion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F215762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corsazinmid (ID);",
"     </li>",
"     <li>",
"      Macrozide (CO);",
"     </li>",
"     <li>",
"      Mide (TW);",
"     </li>",
"     <li>",
"      Neotibi (ID);",
"     </li>",
"     <li>",
"      P-Zide (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      P.T.B. (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      P.Z.A. (TW);",
"     </li>",
"     <li>",
"      Piraldina (AE, BG, BH, CY, EG, IL, IN, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pirazimida (ES);",
"     </li>",
"     <li>",
"      Pirazinamida (PE);",
"     </li>",
"     <li>",
"      Pirazinamida Prodes (ES);",
"     </li>",
"     <li>",
"      Pirazinid (TR);",
"     </li>",
"     <li>",
"      Pirilene (FR);",
"     </li>",
"     <li>",
"      Pramide (PT);",
"     </li>",
"     <li>",
"      Pyrafat (AT, DE, HK);",
"     </li>",
"     <li>",
"      Pyramide (TH);",
"     </li>",
"     <li>",
"      Pyramin (PH);",
"     </li>",
"     <li>",
"      Pyrazid (PK);",
"     </li>",
"     <li>",
"      Pyrazinamid (HR, HU, PL);",
"     </li>",
"     <li>",
"      Pyrazinamid Lederle (CH);",
"     </li>",
"     <li>",
"      Pyrazinamid &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Pyrazinamid &rdquo;Medic&rdquo; (DK);",
"     </li>",
"     <li>",
"      Pyrazinamide (TH);",
"     </li>",
"     <li>",
"      PZA (CH);",
"     </li>",
"     <li>",
"      PZA-Ciba (IN, SG);",
"     </li>",
"     <li>",
"      Rifater (MX);",
"     </li>",
"     <li>",
"      Siramid (ID);",
"     </li>",
"     <li>",
"      Tebrazid (BE, CH, LU);",
"     </li>",
"     <li>",
"      Tibicel (ID);",
"     </li>",
"     <li>",
"      Tisamid (CZ, FI);",
"     </li>",
"     <li>",
"      TZM (TH);",
"     </li>",
"     <li>",
"      Zcure (PH);",
"     </li>",
"     <li>",
"      Zinamide (AU, GB, IE, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Converted to pyrazinoic acid in susceptible strains of",
"     <i>",
"      Mycobacterium",
"     </i>",
"     which lowers the pH of the environment; exact mechanism of action has not been elucidated",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bacteriostatic or bactericidal depending on drug's concentration at infection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into body tissues and fluids including liver, lung, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Inflamed meninges: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (4% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, &ldquo;Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-6):1-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bass JB Jr, Farer LS, Hopewell PC, et al, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1994, 149(5):1359-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/8173779/pubmed\" id=\"8173779\" target=\"_blank\">",
"        8173779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC) and American Thoracic Society, &ldquo;Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2003, 52(31):735-9. Available at file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm. Last accessed February 16, 2005.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/12904741/pubmed\" id=\"12904741\" target=\"_blank\">",
"        12904741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Combs DL, O'Brien RJ, and Geiter LJ, &ldquo;USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability: The Report of Final Results,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 112(6):397-406.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(5):651-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/1379145/pubmed\" id=\"1379145\" target=\"_blank\">",
"        1379145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Tuberculosis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(908):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/8412982/pubmed\" id=\"8412982\" target=\"_blank\">",
"        8412982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(5):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/9929528/pubmed\" id=\"9929528\" target=\"_blank\">",
"        9929528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herlevsen P, Nielsen C, and Pedersen JT, &ldquo;Convulsions After Treatment With Pyrazinamide,&rdquo;",
"      <i>",
"       Tubercle",
"      </i>",
"      , 1987, 68(2):145-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/3499016/pubmed\" id=\"3499016\" target=\"_blank\">",
"        3499016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holdiness MR, \"Antituberculosis Drugs and Breast-Feeding,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1984, 144(9):1888.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/6548112/pubmed\" id=\"6548112\" target=\"_blank\">",
"        6548112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(11):784-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/8350889/pubmed\" id=\"8350889\" target=\"_blank\">",
"        8350889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacroix C, Hoang TP, Nouveau J, et al, &ldquo;Pharmacokinetics of Pyrazinamide and Its Metabolites in Healthy Subjects,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1989, 36(4):395-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/2737233/pubmed\" id=\"2737233\" target=\"_blank\">",
"        2737233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-20):1-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1988, 35(3):441-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(11):785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/2124671/pubmed\" id=\"2124671\" target=\"_blank\">",
"        2124671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm\" target=\"_blank\">",
"       file://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm",
"      </a>",
"      . Last accessed February 16, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculous Agents,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1992, 67(2):179-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/1347579/pubmed\" id=\"1347579\" target=\"_blank\">",
"        1347579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Tuberculosis in Aging Adults,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1992, 40(2):178-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31269/abstract-text/1740604/pubmed\" id=\"1740604\" target=\"_blank\">",
"        1740604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9836 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31269=[""].join("\n");
var outline_f30_34_31269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215809\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215775\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215792\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215777\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215752\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215737\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215755\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215807\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215759\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215741\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299964\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215746\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215748\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215781\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375013\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215761\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215750\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215762\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215740\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215758\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/39/29300?source=related_link\">",
"      Pyrazinamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/48/16132?source=related_link\">",
"      Pyrazinamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31270="Spectrum of hypoplastic left heart syndrome";
var content_f30_34_31270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Spectrum of hypoplastic left heart syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The spectrum of hypoplastic left heart syndrome (HLHS).",
"    <br>",
"     (Panel A) Aortic atresia with mitral atresia is the most extreme form of HLHS. The left ventricle (LV) is diminutive. The ascending aorta and arch are extremely hypoplastic, and flow is retrograde. Systemic output is ductal dependent.",
"     <br>",
"      (Panel B) Aortic atresia with a patent mitral valve. As in aortic atresia, the ascending aorta and arch are hypoplastic and all systemic output is ductal dependent. There is inflow without outflow. As a result, the left ventricle is hypertensive with hypertrophy and endocardial fibroelastosis. The left ventricular mass can be greater than normal and result in distortion of the inflow of the right ventricle, resulting in tricuspid valve insufficiency.",
"      <br>",
"       (Panel C) Aortic valve stenosis with a patent mitral valve. The left ventricle is hypoplastic, but antegrade flow through the aortic valve persists. The degree of aortic and arch hypoplasia is less than that observed with aortic atresia. This end of the spectrum of hypoplastic left heart syndrome blends smoothly into critical aortic stenosis, and decision making concerning suitability for two-ventricle repair can be challenging.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7th, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31270=[""].join("\n");
var outline_f30_34_31270=null;
var title_f30_34_31271="Trimipramine: Drug information";
var content_f30_34_31271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimipramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/18/21797?source=see_link\">",
"    see \"Trimipramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Surmontil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trimip&reg;;",
"     </li>",
"     <li>",
"      Nu-Trimipramine;",
"     </li>",
"     <li>",
"      Rhotrimine&reg;;",
"     </li>",
"     <li>",
"      Surmontil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Outpatients: Initial: 75 mg/day in divided doses; may increase to 150 mg/day; Maintenance: 50-150 mg/day as a single bedtime dose; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inpatients: Initial: 100 mg /day in divided doses; may increase to 200 mg/day; if no improvement after 2-3 weeks, dose may be increased to 250-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of trimipramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing trimipramine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate trimipramine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving trimipramine and potential benefits outweigh potential risks, discontinue trimipramine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume trimipramine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11587724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Adolescents: Oral: Initial: 50 mg/day; gradually increase dose to 100 mg/day; Maintenance: Lowest effective dose at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 50 mg/day; gradually increase dose to 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Surmontil&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7875057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM330750.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM330750.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trimipramine may be confused with triamterene",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, facial edema, flushing, heart block, hyper-/hypotension, MI, palpitation, stroke, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, confusion, delusions, disorientation, dizziness, drowsiness, EEG abnormalities, exacerbation of psychosis, fatigue, hallucinations, headache, hypomania, insomnia, nightmares, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, galactorrhea, gynecomastia, hyper-/hypoglycemia, libido (changes in), parotid swelling, syndrome of inappropriate ADH secretion (SIADH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, paralytic ileus, stomatitis, tongue edema, unpleasant taste, tongue edema, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Delayed/difficult urination, impotence, polyuria, testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Ataxia, extrapyramidal symptoms, incoordination, numbness, paresthesia, peripheral neuropathy, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, disturbances in accommodation, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimipramine, any component of the formulation, or other dibenzodiazepines; use in a patient during the acute recovery phase of MI; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either trimipramine or the MAO inhibitor); initiation of trimipramine in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Trimipramine is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Trimipramine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension. May also cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F231666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Surmontil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $354.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $580.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $817.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Trimipramine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $72.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $119.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $173.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F231645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure and pulse rate prior to and during initial therapy; evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); signs/symptoms of serotonin syndrome; monitor weight; ECG in older adults",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trimip (MY);",
"     </li>",
"     <li>",
"      Sapilent (HN, HU);",
"     </li>",
"     <li>",
"      Stangyl (AT, DE);",
"     </li>",
"     <li>",
"      Sumontil (JP);",
"     </li>",
"     <li>",
"      Surmontil (AE, AR, AU, BB, BE, BH, BM, BS, BZ, CH, CY, DK, EG, ES, FI, FR, GB, GY, HK, IE, IN, IQ, IT, JM, KW, LU, NL, NO, NZ, OM, PH, PK, PT, QA, SE, SR, TT, YE);",
"     </li>",
"     <li>",
"      Trimin (CH);",
"     </li>",
"     <li>",
"      Tydamine (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17-48 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%; free drug: 3% to 7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; significant first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 18% to 63%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 16-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Druid H and Holmgren P, &ldquo;Fatal Seizures Associated With Trimipramine Overdose,&rdquo;",
"      <i>",
"       Forensic Sci Int",
"      </i>",
"      , 1991, 49(1):75-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/2032669/pubmed\" id=\"2032669\" target=\"_blank\">",
"        2032669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nebinger P and Koel M, &ldquo;Specificity Data of the Tricyclic Antidepressants Assay by Fluorescent Polarization Immunoassay,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1990, 14(4):219-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/2395342/pubmed\" id=\"2395342\" target=\"_blank\">",
"        2395342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Remy AJ, Larrey D, Pageaux GP, et al, &ldquo;Cross Hepatotoxicity Between Tricyclic Antidepressants and Phenothiazines,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 1995, 7(4):373-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/7600146/pubmed\" id=\"7600146\" target=\"_blank\">",
"        7600146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/34/31271/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10025 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31271=[""].join("\n");
var outline_f30_34_31271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708872\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231670\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231671\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231674\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11587724\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231675\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231648\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7875057\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231651\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231711\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231701\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231654\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231636\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231699\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231641\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231666\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231643\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447528\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231657\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231645\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231658\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231653\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10025|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/18/21797?source=related_link\">",
"      Trimipramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31272="Apparent life-threatening event in infants";
var content_f30_34_31272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Apparent life-threatening event in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Michael J Corwin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31272/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/34/31272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An apparent life-threatening event (ALTE) is not a specific diagnosis but a description of an acute, unexpected change in an infant's breathing behavior that is frightening to the caretaker and that includes some combination of the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apnea &mdash; usually no respiratory effort (central) or sometimes effort with difficulty (obstructive)",
"     </li>",
"     <li>",
"      Color change &mdash; usually cyanotic or pallid but occasionally erythematous or plethoric",
"     </li>",
"     <li>",
"      Marked change in muscle tone (usually limpness or rarely rigidity)",
"     </li>",
"     <li>",
"      Choking or gagging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, the observer fears that the infant has died. Recovery occurs only after stimulation or resuscitation. However, episodes are often mislabeled as \"ALTEs\" even when a parent reports that the child resumed normal breathing after simply being picked up and patted.",
"   </p>",
"   <p>",
"    After early anecdotal reports of deaths from sudden infant death syndrome (SIDS) in infants with recurrent apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/2\">",
"     2",
"    </a>",
"    ], enormous amounts of attention, research, and clinical resources were focused on the problem of ALTE in infants. Although various cardiorespiratory, autonomic, and neurophysiologic differences have been demonstrated in ALTE infants as a group, these findings have NOT distinguished individual ALTE infants from normal controls nor provided premortem markers for the risk of SIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/3\">",
"     3",
"    </a>",
"    ]. ALTE infants represent a heterogeneous group of patients of varying ages with diverse pathophysiology. As a result, appropriate evaluation and management should be individualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize that ALTE is not a specific diagnosis; rather, it describes a \"chief complaint\" that brings an infant to medical attention. The term ALTE was coined by the 1986 National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring. ALTE replaced misleading terms, such as \"near-miss SIDS\" or \"aborted crib deaths\", which implied a direct association between these symptoms and SIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/1\">",
"     1",
"    </a>",
"    ]. A substantial proportion of ALTEs are medically insignificant, since the case definition depends upon the observations of frightened, medically untrained caretakers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of ALTEs is estimated to be 0.05 to 1 percent in population-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lack of causal relationship between ALTE and SIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between SIDS and ALTE had been suggested because of prior ALTE events in 5 percent of SIDS victims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/9\">",
"     9",
"    </a>",
"    ] and early anecdotal reports of SIDS in infants with recurrent apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the vast majority of SIDS victims do not experience apnea prior to death. Furthermore, studies over the past two decades have failed to confirm a causal relationship between preexisting apnea and SIDS. Several other factors argue against a relationship between SIDS and ALTE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ALTE refers to a heterogeneous group of problems ranging from benign to near-fatal, whereas SIDS denotes a fatal problem.",
"     </li>",
"     <li>",
"      The case definition in ALTE depends upon parental observations, which have been shown to be unreliable in several studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/4,10-14\">",
"       4,10-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over 80 percent of SIDS deaths occur between midnight and 6 AM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/15\">",
"       15",
"      </a>",
"      ], whereas 82 percent of ALTE episodes occur between 8 AM and 8 PM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interventions to prevent SIDS (eg, supine sleeping) have not resulted in a decreased incidence of ALTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The risk factors for SIDS and ALTE differ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In one prospective population-based study, prone sleeping, lack of breast feeding, and maternal smoking were risks for SIDS, whereas behavioral characteristics (eg, repeated apnea, pallor, history of cyanosis, and feeding difficulties) were risk factors for ALTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific cause for the ALTE can be identified in over one-half of patients after a careful history, physical examination, and appropriate laboratory evaluation (",
"    <a class=\"graphic graphic_table graphicRef51356 \" href=\"mobipreview.htm?17/20/17741\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/20\">",
"     20",
"    </a>",
"    ]. Gastroesophageal reflux, neurologic problems (such as seizures or breath-holding spells), and infection account for the greatest number of ALTE-type episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroesophageal reflux is frequently invoked to describe feeding-associated events, and is diagnosed in approximately 30 percent of infants presenting with an ALTE. However, there is little evidence that this represents pathologic reflux or that the events can be prevented by treatment for reflux, as discussed below. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'ALTE and gastroesophageal reflux'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A central nervous system disorder (most presenting as seizures, but ventricular hemorrhage or hydrocephalus were found in some) was ultimately diagnosed in 15 to 20 percent of infants with an ALTE presentation (data from two case series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infrequent causes are cardiac disease, upper airway obstruction, metabolic disorders, anaphylaxis, and other miscellaneous conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accidental or intentional poisoning may be responsible for a small number of ALTE in some populations. In one institution, toxicology screens were performed in nearly half of the infants evaluated for ALTE. Of 274 results, 8 percent revealed clinically significant ingestions. Five percent of the infants screened positive for over-the-counter cold medications, although none of the parents admitted to administering these [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/25\">",
"       25",
"      </a>",
"      ]. However, the extent to which the ingestion may have contributed to the ALTE is uncertain.",
"     </li>",
"     <li>",
"      The remaining cases are considered idiopathic if no cause can be identified after a thorough assessment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ALTE and gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vomiting or regurgitation occurs commonly in patients with apparent life-threatening events (ALTE), but also in healthy infants. An association between reflux and apnea or bradycardia has not been demonstrated convincingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. As a result, the role of reflux in infants with ALTEs is uncertain. Even when an episode of gastroesophageal reflux appears to have immediately preceded the ALTE, the direct cause of the respiratory event is probably laryngospasm. The reflux may have triggered the laryngospasm, but this does not mean that it is pathologic or that treatment of reflux will prevent future ALTEs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Laryngospasm also may occur during feeding in the absence of gastroesophageal reflux.",
"   </p>",
"   <p>",
"    Esophageal pH monitoring may be useful in the evaluation but only if an apparent event occurs while monitoring and can be temporally associated with a preceding episode of reflux by using simultaneous polysomnography or continuous oxygen saturation monitoring.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    esophagrams are neither sensitive nor specific for detecting pathologic gastroesophageal reflux in infants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=see_link&amp;anchor=H6#H6\">",
"     \"Gastroesophageal reflux in infants\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ALTE is more likely to be related to reflux, and the infant is therefore more likely to respond to antireflux therapy when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gross emesis or oral regurgitation occurs at the time of the ALTE.",
"     </li>",
"     <li>",
"      Episodes occur while the infant is awake and supine.",
"     </li>",
"     <li>",
"      ALTE is characterized by obstructive apnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In infants with these characteristics, low-risk medical interventions (eg, thickening of feeds, trial of a milk-free diet, acid suppression, and possibly prokinetic agents) may be used, but these interventions should not replace or delay an evaluation for other causes of ALTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/30\">",
"     30",
"    </a>",
"    ]. Because a causal association between reflux and ALTE rarely is established with certainty, and because the overall risk for death in these infants is low, invasive approaches such as antireflux surgery are rarely appropriate for this type of patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=see_link&amp;anchor=H19#H19\">",
"     \"Gastroesophageal reflux in infants\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Feeding difficulties may be associated with ALTE even in the absence of gastroesophageal reflux. In a study of infants evaluated for ALTE in Austria, feeding difficulties were associated with a more than two-fold increase in ALTE events (multivariate relative risk 2.5, 95% CI 1.3-4.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ALTE and child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following pattern of events should raise concern for the possibility of intentional suffocation (Munchausen syndrome by proxy, a form of child abuse):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent, severe ALTE events requiring cardiopulmonary resuscitation (CPR) that occur only in the presence of a single caretaker,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      A thorough diagnostic evaluation reveals no reasonable explanation for these repetitive events &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these cases, the deceptive parent (usually the mother) appears to be a dedicated caretaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. This parent often has a health care employment background and a personal history of unusual illnesses. Extraordinary illnesses or SIDS may have occurred in previous siblings. A large case series of patients diagnosed with covert video surveillance provides a shocking chronicle of historical markers and clinical observations in infants who suffer life-threatening child abuse from intentional suffocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abusive head injury is another form of child abuse that must be considered in infants with ALTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/36\">",
"     36",
"    </a>",
"    ]. In a prospective series of 243 infants (&lt;12 months) admitted to a tertiary care medical center for evaluation of ALTE, six (2.5 percent) were diagnosed with abusive head injuries, two of whom died in the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of physical findings such as facial injury or bruising or a bulging anterior fontanel should prompt a thorough evaluation for abusive head injury. In a series of infants evaluated at a single center for ALTE, other factors that suggest abusive head injury include recurrent episodes of ALTE, vomiting or unexplained irritability, and a call by the caretaker to Emergency Medical Services (911) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/38\">",
"     38",
"    </a>",
"    ]. If abusive head injury is suspected, further investigation should include neuroimaging and dilated funduscopic examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retinal hemorrhages are associated with ALTE from abusive head trauma, but not other causes of ALTE. For example, an observational study of 108 children two years of age and younger admitted for an ALTE found that none had retinal hemorrhages on indirect ophthalmoscopy performed by an ophthalmologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of the infant who presents with ALTE includes a thorough history and examination with additional testing directed by the findings of the initial clinical assessment. In a series of infants admitted to a tertiary center with ALTE, the diagnosis was made on the basis of the history and physical examination alone in 21 percent of cases, and confirmed with testing prompted by the history and physical examination in an additional 49 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/40\">",
"     40",
"    </a>",
"    ]. Furthermore, 18 percent of the tests ordered were positive, and only 6 percent contributed to the diagnosis.",
"   </p>",
"   <p>",
"    If the detailed description of the event suggests that the child was physiologically compromised, then in-hospital observation with cardiorespiratory monitoring is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important diagnostic tool is a detailed description of the event and intervention obtained from the caretaker who witnessed the episode and any emergency personnel involved in the case. The key elements in the history are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef54418 \" href=\"mobipreview.htm?39/39/40571\">",
"     table 2",
"    </a>",
"    ). With this information, the physician can determine whether the episode was truly life-threatening or merely frightening, a key factor in subsequent management decisions.",
"   </p>",
"   <p>",
"    In addition, the history should include information about any previous apneic events, recent illnesses or symptoms, the pregnancy and perinatal period, the infant's usual behavior, sleep and feeding habits, a family history (including a history of siblings with ALTE, early deaths, genetic, metabolic, cardiac, and neurologic problems), a social history (including the presence of smoking, alcohol or substance use in the home, and a list of medications in the home) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/14\">",
"     14",
"    </a>",
"    ]. The family should be asked specifically about the possibility of accidental or intentional administration of poisons or medications, including over-the-counter cold preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/25\">",
"     25",
"    </a>",
"    ]. Such information may help in defining an etiology for the event (eg, heritable metabolic disease, unintentional or intentional ingestion).",
"   </p>",
"   <p>",
"    Specific characteristics of the history that might suggest an association with gastroesophageal reflux are discussed separately. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'ALTE and gastroesophageal reflux'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A history of previous episodes of ALTE should particularly prompt consideration of abusive head trauma. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'ALTE and child abuse'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants presenting with an ALTE should undergo careful physical examination, with particular attention to abnormalities in the neurologic, respiratory, and cardiac systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41\">",
"     41",
"    </a>",
"    ]. The examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of height, weight, and head circumference and comparison of these values to standards for age and sex",
"     </li>",
"     <li>",
"      Measurement of vital signs",
"     </li>",
"     <li>",
"      Examination for physical signs of trauma (bruising, bulging anterior fontanel)",
"     </li>",
"     <li>",
"      Developmental assessment",
"     </li>",
"     <li>",
"      Evaluation for upper airway obstruction, including assessment of facial dysmorphism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A dilated funduscopic examination should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/37,44\">",
"     37,44",
"    </a>",
"    ], particularly if abusive head trauma is suspected. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'ALTE and child abuse'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history and physical examination suggest that the event was not life-threatening, or if a probable explanation for the event is identified (eg, transient laryngospasm after an episode of gastroesophageal reflux), then no laboratory evaluation may be required. In some cases, a limited evaluation is performed to confirm the suspected diagnosis.",
"   </p>",
"   <p>",
"    When the event is judged to be truly life-threatening and an explanation for the ALTE is not apparent based on the history and physical examination, the initial laboratory evaluation usually (but not necessarily) includes a complete blood count, urinalysis, plasma concentrations of glucose, electrolytes, blood urea nitrogen (BUN), calcium, magnesium, chest radiograph, and electrocardiogram. In addition, particularly if the infant has a change in sensorium, a toxicology screen to detect accidental or intentional ingestions of poisons or medications, including over-the-counter cold preparations and ethanol, may be of value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/25,45\">",
"     25,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further specific diagnostic studies may be indicated in selected cases (",
"    <a class=\"graphic graphic_table graphicRef67825 \" href=\"mobipreview.htm?18/35/19004\">",
"     table 3",
"    </a>",
"    ). The additional evaluation depends upon the presenting symptoms and findings in the history, examination, and initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41,46,47\">",
"     41,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the consecutive series of 243 infants with ALTE described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/40\">",
"     40",
"    </a>",
"    ], among 171 infants in whom a particular diagnosis was suggested by the history and examination, the following tests contributed to establishing the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood counts, chemistries, and cultures",
"     </li>",
"     <li>",
"      CSF fluid analysis and cultures",
"     </li>",
"     <li>",
"      Metabolic screening",
"     </li>",
"     <li>",
"      Screening for respiratory pathogens",
"     </li>",
"     <li>",
"      Screening for gastroesophageal reflux",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Brain neuroimaging",
"     </li>",
"     <li>",
"      Skeletal survey",
"     </li>",
"     <li>",
"      Electroencephalogram",
"     </li>",
"     <li>",
"      Echocardiogram",
"     </li>",
"     <li>",
"      Polysomnography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the 72 infants in whom the history and examination were noncontributory, only the following tests contributed to establishing the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      White blood cell count",
"     </li>",
"     <li>",
"      Screening for gastroesophageal reflux",
"     </li>",
"     <li>",
"      Urine analysis and culture",
"     </li>",
"     <li>",
"      Brain neuroimaging",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"     <li>",
"      Polysomnography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consultation with a specialist in infant apnea and developmental aspects of respiratory control can be useful. Polysomnography may be helpful in the evaluation of on-going respiratory, cardiac, and neurologic dysfunction during sleep. Some authors believe that it can contribute to the prediction of subsequent ALTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], but it cannot predict the risk for future ALTE episodes or SIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multi-channel polysomnography typically includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An EEG to evaluate the sleep-wake state of the infant",
"     </li>",
"     <li>",
"      Measurement of thoracic and abdominal wall movement to evaluate breathing patterns and apnea characteristics (if present)",
"     </li>",
"     <li>",
"      Electrocardiogram sensors to evaluate heart rate",
"     </li>",
"     <li>",
"      Oximetry to measure oxygen saturation during sleep and after apnea",
"     </li>",
"     <li>",
"      Airflow changes (using thermistors that sense alterations in heat exchange or an end-tidal CO2 monitor)",
"     </li>",
"     <li>",
"      Esophageal pH monitoring can be added when a temporal relationship between gastroesophageal reflux and apnea is strongly suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multichannel polysomnograms are to be distinguished from two-channel \"pneumograms\", which should not be used in the evaluation of ALTE. \"Pneumograms\" provide continuous 12 to 24 hour recordings of chest movement and heart rate but provide no data on oxygenation or airway obstruction.",
"   </p>",
"   <p>",
"    For infants with a history of recurrent difficulties while feeding (eg, observations of choking or repeated ALTEs) a videofluoroscopic swallowing study may be useful to evaluate for swallowing dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of ALTE must be taken seriously, even if the infant appears entirely well by the time he or she is evaluated. The apparent well-being should not be considered evidence that a potentially life-threatening event with successful resuscitation did not occur if the clinical history indicates otherwise.",
"   </p>",
"   <p>",
"    In-hospital observation with cardiorespiratory monitoring is indicated for infants whose initial evaluation (whether by history, examination, or other diagnostic studies) suggests physiologic compromise. This includes infants with a history of more than one ALTE event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/51\">",
"     51",
"    </a>",
"    ]. A brief period of in-hospital observation and monitoring immediately after an ALTE may provide important clinical information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional episodes may be witnessed by medical personnel. In one case series, the occurrence of documented in-hospital events during the initial investigation period increased the likelihood of additional events at home, especially in the first month after the initial event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serious, underlying medical conditions (eg, hypoventilation or hypoxemia) may become apparent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/46,47,52\">",
"       46,47,52",
"      </a>",
"      ]. Documentation of apnea or bradycardia in association with clinical findings of inadequate respiratory effort, color change, or loss of tone will confirm the need for more specialized diagnostic studies (eg, extended Holter monitoring, esophageal pH monitoring, epilepsy monitoring, polysomnography, computed tomography or magnetic resonance imaging of the central nervous system, metabolic studies, or more invasive studies such as bronchoscopy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical or surgical treatment of an underlying disorder is possible in about 50 percent of ALTE cases if additional studies identify a specific cause of the ALTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/16,53\">",
"     16,53",
"    </a>",
"    ]. Management of the remaining 50 percent of cases depends upon the clinical history and the identification of infants at potentially high risk for adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk factors for recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have reported a high frequency of subsequent apnea in infants with idiopathic ALTE episodes. The clinical significance of these subsequent \"alarm conditions\" is questionable because of the high incidence (&gt;90 percent) of false apnea alarms on home monitors and the unreliability of parental observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/4,10-14\">",
"     4,10-14",
"    </a>",
"    ]. As an example, 90 percent of parents report repeated alarms, but only 10 percent of children with an ALTE history have additional events that are considered clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for clinically significant recurrences include immaturity, a history of multiple ALTE preceding the hospital admission, and a viral respiratory tract infection, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 59 infants presenting to an emergency department with an ALTE sought to identify characteristics that predicted recurrence and, therefore, required hospital admission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/54\">",
"       54",
"      </a>",
"      ]. Eight of these infants subsequently had serious events that required inpatient management (including apnea, infection, or seizures). All eight infants were either younger than one month of age or had a history of multiple ALTE during the 24 hours prior to admission. Although this study is small and lacks external validation, it suggests these may be useful characteristics for identifying infants at high risk.",
"     </li>",
"     <li>",
"      In another study of 625 infants admitted because of an ALTE, 7.4 percent had recurrence with an extreme event (defined as central apnea lasting more than 30 seconds, or extreme bradycardia or oxygen desaturation &lt;80 percent lasting more than 10 seconds) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. In most cases, the event occurred within 24 hours of the hospital admission. The main risk factors for recurrence with an extreme event were viral respiratory tract infection, postconceptional age under 43 weeks, or history of prematurity (even if postconceptional age &gt;43 weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The caregivers of infants who have had an ALTE should receive training in standard cardiopulmonary resuscitation (CPR) for infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41\">",
"     41",
"    </a>",
"    ]. They should also be instructed in safe infant care practices including supine sleep position with face free, safe sleeping environments (avoiding adult or loose bedding, excessive clothing, extreme room temperatures), and elimination of prenatal and postnatal exposure to tobacco smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Home monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diverse characteristics of infants with a history of ALTE preclude universal policies regarding the use of home CR monitoring. The decision should be made on a case-by-case basis after considering with the family the potential benefits, uncertainties, and stresses involved.",
"   </p>",
"   <p>",
"    Studies of infants with a history of ALTE but who are otherwise asymptomatic have failed to demonstrate a therapeutic benefit of home CR monitoring. However, in selected cases, monitor recordings may provide some diagnostic value, or may provide reassurance that clinically important events are not occurring. Providers and families should recognize that currently available home monitors only detect chest wall movement and heart rate. For some infants, particularly those in whom obstructive apnea is suspected, monitoring oxygen saturation by pulse oximetry may be a more appropriate physiologic signal to monitor. These issues are discussed in more detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21414?source=see_link\">",
"     \"Use of home cardiorespiratory monitors in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALTEs that occur in infants with a history of prematurity usually represent an immaturity of respiratory control and generally resolve with maturation. In a longitudinal cohort study of 1079 infants, cardiorespiratory events recorded on home monitors were compared in healthy term infants, term infants with idiopathic ALTE, preterm infants with idiopathic ALTE, term siblings of SIDS victims, preterm siblings of SIDS victims, symptomatic preterm infants, and asymptomatic preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/56\">",
"     56",
"    </a>",
"    ]. Conventional alarm events were common among all groups, but only preterm infants were at increased risk of extreme alarm events, and these events disappeared once those infants reached 43 weeks postconceptional age. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Risk factors for recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of subsequent death in ALTE infants is estimated to be less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/3\">",
"     3",
"    </a>",
"    ], but the heterogeneity of the underlying conditions that present as apparent life threatening events limits the clinical usefulness of this estimate. Certain patient groups within the ALTE population are believed to have a greater mortality risk. Infants with recurrent ALTE requiring CPR have a very high risk of subsequent SIDS, ranging from 10 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Unusual diagnoses, including metabolic diseases, neurodegenerative problems, or intentional suffocation, should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall long-term outcome for \"uncomplicated\" ALTE infants is excellent. Controlled follow-up studies have reported a slight increase in subtle neurologic abnormalities at one to three years and an increased frequency of breath-holding spells; however, no differences were observed at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31272/abstract/16,59,60\">",
"     16,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics: (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/40/7811?source=see_link\">",
"       \"Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An apparent life-threatening event (ALTE) is not a specific diagnosis, but a description of abrupt changes in an infant's breathing, color, and state that are frightening to the caregiver. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALTE is not considered a precursor or risk factor for SIDS. The vast majority of SIDS victims do not experience apnea prior to death, and the epidemiology and risk factors for SIDS are very different from those for ALTE. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lack of causal relationship between ALTE and SIDS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical efforts should be focused on diagnosis of specific medical conditions for which specific treatments can be identified (",
"      <a class=\"graphic graphic_table graphicRef51356 \" href=\"mobipreview.htm?17/20/17741\">",
"       table 1",
"      </a>",
"      ). In healthy infants experiencing a single ALTE, the exact cause is often never identified. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important diagnostic tool is a detailed description of the event and intervention obtained from the caretaker who witnessed the episode (",
"      <a class=\"graphic graphic_table graphicRef54418 \" href=\"mobipreview.htm?39/39/40571\">",
"       table 2",
"      </a>",
"      ). With this information, the physician can determine whether the episode was truly life-threatening or merely frightening, a key factor in subsequent management decisions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the history and physical examination suggest that the event was not life-threatening, or if a probable explanation for the event is identified (eg, transient laryngospasm after an episode of gastroesophageal reflux), then no laboratory evaluation may be required. Further specific diagnostic studies may be indicated in selected cases (",
"      <a class=\"graphic graphic_table graphicRef67825 \" href=\"mobipreview.htm?18/35/19004\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of reflux in infants with ALTEs is uncertain. When an episode of gastroesophageal reflux appears to have immediately preceded the ALTE, the direct cause of the respiratory event is probably laryngospasm. The reflux may have triggered the laryngospasm, but this does not mean that the reflux is pathologic or that treatment of reflux will prevent future ALTEs. Laryngospasm also may occur during feeding in the absence of gastroesophageal reflux. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'ALTE and gastroesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of child abuse should be considered when an infant suffers recurrent, severe ALTE events requiring cardiopulmonary resuscitation (CPR) that occur only in the presence of a single caretaker,",
"      <strong>",
"       and",
"      </strong>",
"      a thorough diagnostic evaluation reveals no reasonable explanation for these dramatic repetitive events. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ALTE and child abuse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When ALTEs are recurrent and not explained by maturational delay (as in persistent apnea of prematurity), then an aggressive diagnostic approach, as outlined above, is required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/1\">",
"      National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring, Sept 29 to Oct 1, 1986. Pediatrics 1987; 79:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/2\">",
"      Steinschneider A. Prolonged apnea and the sudden infant death syndrome: clinical and laboratory observations. Pediatrics 1972; 50:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/3\">",
"      Brooks JG. Apparent life-threatening events and apnea of infancy. Clin Perinatol 1992; 19:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/4\">",
"      Krongrad E. Infants at high risk for sudden infant death syndrome??? Have they been identified???--A commentary. Pediatrics 1991; 88:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/5\">",
"      Polberger S, Svenningsen NW. Early neonatal sudden infant death and near death of fullterm infants in maternity wards. Acta Paediatr Scand 1985; 74:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/6\">",
"      Davis N, Sweeney LB. Apnea of infancy--a clinical problem. West J Med 1986; 144:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/7\">",
"      Wennergren G, Milerad J, Lagercrantz H, et al. The epidemiology of sudden infant death syndrome and attacks of lifelessness in Sweden. Acta Paediatr Scand 1987; 76:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/8\">",
"      Sunkaran K, McKenna A, O'Donnell M, et al. Apparent life-threatening prolonged infant apnea in Saskatchewan. West J Med 1989; 150:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/9\">",
"      Hoffman HJ, Damus K, Hillman L, Krongrad E. Risk factors for SIDS. Results of the National Institute of Child Health and Human Development SIDS Cooperative Epidemiological Study. Ann N Y Acad Sci 1988; 533:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/10\">",
"      Krongrad E, O'Neill L. Near miss sudden infant death syndrome episodes? A clinical and electrocardiographic correlation. Pediatrics 1986; 77:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/11\">",
"      Nathanson I, O'Donnell J, Commins MF. Cardiorespiratory patterns during alarms in infants using apnea/bradycardia monitors. Am J Dis Child 1989; 143:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/12\">",
"      Steinschneider A, Santos V. Parental reports of apnea and bradycardia: temporal characteristics and accuracy. Pediatrics 1991; 88:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/13\">",
"      Weese-Mayer DE, Silvestri JM. Documented monitoring: an alarming turn of events. Clin Perinatol 1992; 19:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/14\">",
"      C&ocirc;t&eacute; A, Hum C, Brouillette RT, Themens M. Frequency and timing of recurrent events in infants using home cardiorespiratory monitors. J Pediatr 1998; 132:783.",
"     </a>",
"    </li>",
"    <li>",
"     Fleming, P, Blair, P, Bacon, C, et al. Sudden unexpected deaths in infancy: the CESDI SUDI studies 1993-1996. Stationery Office 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/16\">",
"      Kahn A, Groswasser J, Rebuffat E, et al. Sleep and cardiorespiratory characteristics of infant victims of sudden death: a prospective case-control study. Sleep 1992; 15:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/17\">",
"      Kiechl-Kohlendorfer U, Hof D, Peglow UP, et al. Epidemiology of apparent life threatening events. Arch Dis Child 2005; 90:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/18\">",
"      Esani N, Hodgman JE, Ehsani N, Hoppenbrouwers T. Apparent life-threatening events and sudden infant death syndrome: comparison of risk factors. J Pediatr 2008; 152:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/19\">",
"      Hoppenbrouwers T, Hodgman JE, Ramanathan A, Dorey F. Extreme and conventional cardiorespiratory events and epidemiologic risk factors for SIDS. J Pediatr 2008; 152:636.",
"     </a>",
"    </li>",
"    <li>",
"     Kahn, A, Rebuffat, E, Franco, P, et al. Apparent life-threatening events and apnea of infancy. In: Respiratory control disorders in infants and children. Berckerman, RC, Brouillette, RT, Hunt, CE (Eds), Williams and Wilkins, New York 1992. p.178.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/21\">",
"      McGovern MC, Smith MB. Causes of apparent life threatening events in infants: a systematic review. Arch Dis Child 2004; 89:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/22\">",
"      Gray C, Davies F, Molyneux E. Apparent life-threatening events presenting to a pediatric emergency department. Pediatr Emerg Care 1999; 15:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/23\">",
"      Genizi J, Pillar G, Ravid S, Shahar E. Apparent life-threatening events: neurological correlates and the mandatory work-up. J Child Neurol 2008; 23:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/24\">",
"      Hoki R, Bonkowsky JL, Minich LL, et al. Cardiac testing and outcomes in infants after an apparent life-threatening event. Arch Dis Child 2012; 97:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/25\">",
"      Pitetti RD, Whitman E, Zaylor A. Accidental and nonaccidental poisonings as a cause of apparent life-threatening events in infants. Pediatrics 2008; 122:e359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/26\">",
"      Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 2:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/27\">",
"      Di Fiore JM, Arko M, Whitehouse M, et al. Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. Pediatrics 2005; 116:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/28\">",
"      Mousa H, Woodley FW, Metheney M, Hayes J. Testing the association between gastroesophageal reflux and apnea in infants. J Pediatr Gastroenterol Nutr 2005; 41:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/29\">",
"      Orenstein SR. An overview of reflux-associated disorders in infants: apnea, laryngospasm, and aspiration. Am J Med 2001; 111 Suppl 8A:60S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/30\">",
"      Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009; 104:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/31\">",
"      Meadow R. Munchausen syndrome by proxy. The hinterland of child abuse. Lancet 1977; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/32\">",
"      Southall DP, Stebbens VA, Rees SV, et al. Apnoeic episodes induced by smothering: two cases identified by covert video surveillance. Br Med J (Clin Res Ed) 1987; 294:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/33\">",
"      Samuels MP, McClaughlin W, Jacobson RR, et al. Fourteen cases of imposed upper airway obstruction. Arch Dis Child 1992; 67:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/34\">",
"      Meadow R. Suffocation, recurrent apnea, and sudden infant death. J Pediatr 1990; 117:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/35\">",
"      Southall DP, Plunkett MC, Banks MW, et al. Covert video recordings of life-threatening child abuse: lessons for child protection. Pediatrics 1997; 100:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/36\">",
"      Parker K, Pitetti R. Mortality and child abuse in children presenting with apparent life-threatening events. Pediatr Emerg Care 2011; 27:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/37\">",
"      Altman RL, Brand DA, Forman S, et al. Abusive head injury as a cause of apparent life-threatening events in infancy. Arch Pediatr Adolesc Med 2003; 157:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/38\">",
"      Guenther E, Powers A, Srivastava R, Bonkowsky JL. Abusive head trauma in children presenting with an apparent life-threatening event. J Pediatr 2010; 157:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/39\">",
"      Curcoy AI, Trenchs V, Morales M, et al. Retinal hemorrhages and apparent life-threatening events. Pediatr Emerg Care 2010; 26:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/40\">",
"      Brand DA, Altman RL, Purtill K, Edwards KS. Yield of diagnostic testing in infants who have had an apparent life-threatening event. Pediatrics 2005; 115:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/41\">",
"      Kahn A, European Society for the Study and Prevention of Infant Death. Recommended clinical evaluation of infants with an apparent life-threatening event. Consensus document of the European Society for the Study and Prevention of Infant Death, 2003. Eur J Pediatr 2004; 163:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/42\">",
"      Guilleminault C, Pelayo R, Leger D, Philip P. Apparent life-threatening events, facial dysmorphia and sleep-disordered breathing. Eur J Pediatr 2000; 159:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/43\">",
"      Wilson AC, Moore DJ, Moore MH, et al. Late presentation of upper airway obstruction in Pierre Robin sequence. Arch Dis Child 2000; 83:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/44\">",
"      Pitetti RD, Maffei F, Chang K, et al. Prevalence of retinal hemorrhages and child abuse in children who present with an apparent life-threatening event. Pediatrics 2002; 110:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/45\">",
"      McCormick T, Levine M, Knox O, Claudius I. Ethanol ingestion in two infants under 2 months old: a previously unreported cause of ALTE. Pediatrics 2013; 131:e604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/46\">",
"      De Piero AD, Teach SJ, Chamberlain JM. ED evaluation of infants after an apparent life-threatening event. Am J Emerg Med 2004; 22:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/47\">",
"      Davies F, Gupta R. Apparent life threatening events in infants presenting to an emergency department. Emerg Med J 2002; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/48\">",
"      Farrell PA, Weiner GM, Lemons JA. SIDS, ALTE, apnea, and the use of home monitors. Pediatr Rev 2002; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/49\">",
"      Dani&euml;ls H, Naulaers G, Deroost F, Devlieger H. Polysomnography and home documented monitoring of cardiorespiratory pattern. Arch Dis Child 1999; 81:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/50\">",
"      Rosen CL, Frost JD Jr, Harrison GM. Infant apnea: polygraphic studies and follow-up monitoring. Pediatrics 1983; 71:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/51\">",
"      Kaji AH, Claudius I, Santillanes G, et al. Apparent life-threatening event: multicenter prospective cohort study to develop a clinical decision rule for admission to the hospital. Ann Emerg Med 2013; 61:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/52\">",
"      Samuels MP, Poets CF, Noyes JP, et al. Diagnosis and management after life threatening events in infants and young children who received cardiopulmonary resuscitation. BMJ 1993; 306:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/53\">",
"      Kelly DH, Shannon DC, O'Connell K. Care of infants with near-miss sudden infant death syndrome. Pediatrics 1978; 61:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/54\">",
"      Claudius I, Keens T. Do all infants with apparent life-threatening events need to be admitted? Pediatrics 2007; 119:679.",
"     </a>",
"    </li>",
"    <li>",
"     Al-Kindy, HA, Gelinas, JF, Hatzakis G, Cote, A. Risk Factors for Extreme Events in Infants Hospitalized for Apparent Life-threatening Events. J Pediatr 2008 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/56\">",
"      Ramanathan R, Corwin MJ, Hunt CE, et al. Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for SIDS. JAMA 2001; 285:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/57\">",
"      Kelly DH, Shannon DC. Sudden infant death syndrome and near sudden infant death syndrome: a review of the literature, 1964 to 1982. Pediatr Clin North Am 1982; 29:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/58\">",
"      Oren J, Kelly D, Shannon DC. Identification of a high-risk group for sudden infant death syndrome among infants who were resuscitated for sleep apnea. Pediatrics 1986; 77:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/59\">",
"      Kahn A, Verstraeten F, Blum D. Preliminary report on neurodevelopmental screening in children previously at risk for sudden infant death syndrome. J Pediatr 1984; 105:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31272/abstract/60\">",
"      Kahn A, Sottiaux M, Appelboom-Fondu J, et al. Long-term development of children monitored as infants for an apparent life-threatening event during sleep: a 10-year follow-up study. Pediatrics 1989; 83:668.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6365 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-E4F9E9D48D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31272=[""].join("\n");
var outline_f30_34_31272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lack of causal relationship between ALTE and SIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALTE and gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALTE and child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk factors for recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Home monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6365|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/20/17741\" title=\"table 1\">",
"      Differential diagnosis of apparent life-threatening event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/39/40571\" title=\"table 2\">",
"      History in ALTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/35/19004\" title=\"table 3\">",
"      Additional evaluation in ALTE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/40/7811?source=related_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21414?source=related_link\">",
"      Use of home cardiorespiratory monitors in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31273="CD1a stain LCH";
var content_f30_34_31273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Lymph node biopsy in Langerhans cell histiocytosis CD1a stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The lesion fills and expands lymph node sinuses, and the Langerhans cells are associated with eosinophils and giant cells. Hematoxylin-eosin stain.",
"    <br>",
"     (B) Immunostain for CD1a highlights numerous Langerhans cells. Immunochemistry with hematoxylin counterstain.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Ioachim HL, Medeiros LJ. Dendritic cell neoplasms. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31273=[""].join("\n");
var outline_f30_34_31273=null;
var title_f30_34_31274="Evaluation and acute management of cervical spinal column injuries in adults";
var content_f30_34_31274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and acute management of cervical spinal column injuries in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Amy Kaji, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/34/31274/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/34/31274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review discusses the evaluation and initial management of injuries to the cervical spinal column in adults, including the appropriate use of imaging studies. The importance of early recognition and appropriate management of such injuries is underscored by their association with spinal cord injury.",
"   </p>",
"   <p>",
"    Descriptions of the range of spinal column fractures and other injuries, the management of spinal cord injuries, and spinal trauma in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23689?source=see_link\">",
"     \"Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764673\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and clinically important anatomy related to cervical spine injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link&amp;anchor=H2#H2\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link&amp;anchor=H3#H3\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3417199\">",
"    <span class=\"h1\">",
"     MECHANISMS, CLASSIFICATION SCHEMES, AND TYPES OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mechanisms of injury, classification schemes, and important types of cervical spinal column injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link&amp;anchor=H4#H4\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Mechanisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link&amp;anchor=H5#H5\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Cervical spinal column injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prehospital management",
"    </span>",
"    &nbsp;&mdash;&nbsp;General prehospital management of trauma is discussed separately; subjects of particular importance to spinal injury are described below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Spinal immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;First responders should suspect a spinal column injury in any trauma victim, especially in the setting of a motor vehicle collision, assault, fall from a height, or sports-related injury. Spinal immobilization, including backboard, rigid cervical collar, and lateral head supports, should be initiated at the scene, and spine immobilization should be maintained until an unstable spinal injury is excluded. Trauma victims may not think clearly due to head injury, shock, or drug or alcohol intoxication, making cooperation difficult and spinal movement likely. In some cases chemical sedation and rarely, even airway management, may be needed to prevent self-injury.",
"   </p>",
"   <p>",
"    Spinal injury is uncommon in patients with penetrating trauma, and rare in those without evidence of neurologic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/1\">",
"     1",
"    </a>",
"    ]. This lower risk and the possibility of harm from immobilization have led some experts to question the need for spinal immobilization in patients with penetrating trauma who do not manifest neurologic deficits or altered mental status. However, first responders and emergency clinicians must remain cautious when they consider removing spinal immobilization in this setting because victims of penetrating trauma may simultaneously sustain blunt head or neck trauma during an assault. This issue is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=see_link&amp;anchor=H932876#H932876\">",
"     \"Penetrating neck injuries\", section on 'Cervical spine immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical spine injuries are uncommon in cases of self hanging. Morbidity is primarily due to asphyxiation with cerebral anoxia or soft tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Spinal column injury from hanging is seen in executions involving a drop from a height against a knotted rope.",
"   </p>",
"   <p>",
"    The heads of children less than eight years of age are somewhat large in proportion to their bodies, resulting in neck flexion when they are placed supine on a standard backboard. To avoid this, a special backboard with an occipital recess may be used or a rolled sheet can be placed under the child's upper back. Immobilization and protection of the spine in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Helmet removal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motorcycle helmet removal &ndash; Safe removal of a motorcycle helmet requires that manual cervical spine immobilization be maintained continuously, and this can only be done with",
"      <strong>",
"       TWO",
"      </strong>",
"      people.",
"      <br/>",
"      <br/>",
"      The technique is performed as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/4\">",
"       4",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Open any face shield to assess, and if necessary, assist the patient's airway and breathing.",
"     </li>",
"     <li>",
"      The first rescuer, positioned above the head, places one palm along each side of the helmet with fingers on the mandible to prevent head movement. The hands are placed on the outside of the helmet.",
"     </li>",
"     <li>",
"      The second rescuer, positioned beside the patient, then loosens the strap and places one hand at the angle of the mandible and the other hand at the cephalad portion of the posterior neck, just below the rim of the helmet. Maintaining in-line immobilization now becomes the responsibility of the second rescuer.",
"     </li>",
"     <li>",
"      As the first rescuer gradually slides the helmet half-way off, the second rescuer slides his hands from the posterior neck, just below the helmet rim, to the occiput to prevent the head from falling back.",
"     </li>",
"     <li>",
"      The helmet is then completely removed and the cervical spine immobilized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Football helmet removal &ndash; Issues related to whether football and other sports helmets and shoulder padding should be removed, and if so how to remove them, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15815?source=see_link&amp;anchor=H7#H7\">",
"       \"Field care and evaluation of the young athlete with acute neck injury\", section on 'Helmet removal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prehospital personnel should attempt to place a cervical collar, realizing that it may be impossible. To further minimize head motion, towel rolls, foam head blocks, and tape may be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Emergency department (ED) management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial resuscitation and management of the trauma patient is based upon protocols from Advanced Trauma Life Support&reg; (ATLS&reg;), which do not change in the setting of potential spinal column injury. A careful evaluation for potential spinal column injuries is performed as part of the secondary survey. Resuscitation of the trauma patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different types of spinal column injuries are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency clinician should anticipate airway management problems in patients with cervical spinal column injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/5\">",
"     5",
"    </a>",
"    ]. Unstable lesions above C3 may cause immediate respiratory paralysis, and lower cervical lesions may cause delayed phrenic nerve paralysis from ascending edema of the spinal cord. Cervical spinal column injury may be associated with airway obstruction from retropharyngeal hemorrhage, edema, or maxillofacial trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the American College of Surgeons' ATLS&reg; guidelines, orotracheal intubation is the preferred method of airway management for patients with traumatic cardiopulmonary arrest, even with evidence of spinal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/6\">",
"     6",
"    </a>",
"    ]. Orotracheal intubation in conjunction with rapid sequence intubation is recommended for patients who are breathing but unconscious and in need of airway control or ventilatory support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/7\">",
"     7",
"    </a>",
"    ]. In-line spinal stabilization should be maintained throughout the procedure to minimize spinal column movement and reduce the risk of causing or exacerbating a spinal cord injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The authors of one review of in-line spinal stabilization question the technique's utility, pointing out that data supporting the technique come from cadaver studies, observations on uninjured volunteers, and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/8\">",
"     8",
"    </a>",
"    ]. They find little evidence to support the contention that orotracheal intubation without in-line stabilization is unsafe in spinal column injury patients. In addition, in-line stabilization impairs the clinician&rsquo;s view when direct laryngoscopy is performed, increasing the risk for failed intubation and severe hypoxemia, which are associated with poor outcomes in central nervous system injury.",
"   </p>",
"   <p>",
"    Despite the dearth of supporting evidence, we believe clinicians should continue to use in-line stabilization whenever they intubate a patient with a possible spinal column injury until compelling scientific data from randomized trials demonstrate its ineffectiveness. However, the preeminent concern is to protect the airway and oxygenate the patient, and some loss of in-line stabilization is acceptable if necessary to accomplish these ends. The potential difficulty caused by in-line stabilization during laryngoscopy has become less important with the increasing use of video laryngoscopes and other sophisticated airway management tools that improve the clinician&rsquo;s view of the larynx while reducing cervical spine motion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=see_link&amp;anchor=H11#H11\">",
"     \"Devices for difficult emergency airway management in adults\", section on 'Scopes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spinal and neurogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient loss of spinal cord function can occur following spinal column injury. Clinicians must assume that hypotension following trauma results from hemorrhage. Nevertheless, neurogenic shock from spinal cord injury (usually to the superior portion of the spinal cord) may cause hypotension and bradycardia. Neurogenic shock and the management of trauma-related shock are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute traumatic spinal cord injury\", section on 'Transient paralysis and spinal shock'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Secondary survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary survey includes a careful inspection of the patient's entire body, beginning with the head. The secondary survey is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=see_link&amp;anchor=H1929825#H1929825\">",
"     \"Initial management of trauma in adults\", section on 'Secondary evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authorities claim that signs of injury above the clavicles are associated with an increased risk of cervical spinal column injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/6\">",
"     6",
"    </a>",
"    ]. Based on case series, approximately 5 to 10 percent of patients with significant head and facial trauma sustain associated cervical spine injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other studies call this association into question, and emphasize the importance of physiologic indicators, such as depressed neurologic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/11\">",
"     11",
"    </a>",
"    ]. In one retrospective series of 447 consecutive patients with moderate or severe head injury, those with a Glasgow Coma Score below 8 were more likely to have sustained a cervical spine injury (OR 2.77; 95% CI 1.11-7.73) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the secondary survey, the entire spine and paraspinal musculature should be palpated for areas of tenderness or deformity; a step-off in the spine may indicate vertebral subluxation or fracture. Widening of an interspinous space indicates a tear in the posterior ligament complex and a potentially unstable spinal injury, although this finding is difficult to appreciate.",
"   </p>",
"   <p>",
"    A focused but systematic neurologic evaluation should be performed in all patients with a possible spine injury. Clinicians should assess the presence and symmetry of both voluntary and involuntary movements. As examples, priapism may occur with severe spinal cord injury, and an abnormal breathing pattern may indicate a cervical injury, as the diaphragm is innervated by the phrenic nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/13\">",
"     13",
"    </a>",
"    ]. During the neurologic examination, particular attention should be paid to the symmetry of peripheral strength, sensation, reflexes, and proprioception. Any sensory deficits, including the dermatome where they occur, should be noted. Bowel or bladder incontinence is an important finding. Comprehensive summaries of the neurologic examination are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=see_link&amp;anchor=H10928992#H10928992\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although previous iterations of Advanced Trauma Life Support advocated performing a digital rectal examination on all trauma patients during the secondary survey, there is no clear evidence that the examination is an accurate means for detecting spinal cord injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. In specific circumstances, such as pelvic trauma, the rectal examination may provide useful clinical information about the trauma patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain conditions predispose patients to cervical spinal column injury, and thus it is important to obtain the past medical history. As examples, Down syndrome patients are predisposed to atlanto-occipital dislocation and patients with rheumatoid arthritis are prone to rupture of the transverse ligament of C2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of spinal cord injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of spinal cord injury, including the use of glucocorticoids, the National Acute Spinal Cord Injury Study (NASCIS) results, recommendations from neurosurgical societies, and complete versus incomplete spinal cord injury are all discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Details regarding managing complications associated with spinal cord injuries, as well as definitive surgical management, are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute traumatic spinal cord injury\", section on 'Decompression and stabilization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC EVALUATION OF CERVICAL SPINAL COLUMN INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview of imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy persists regarding the most efficient and effective method of cervical spine imaging after blunt trauma; no standard approach has been explicitly defined. The approach we describe here is based upon limited studies and our clinical experience. In all cases of suspected spinal column injury, immobilization of the spine must be maintained until an unstable injury is ruled out. Unstable injuries are listed in the table and discussed in greater detail separately (",
"    <a class=\"graphic graphic_table graphicRef52922 \" href=\"mobipreview.htm?32/28/33228\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamically unstable trauma patients often proceed rapidly to the operating room. These patients are presumed to have an unstable cervical spine injury and spinal immobilization is maintained until radiographic evaluation, generally by computed tomography (CT), can be performed postoperatively.",
"   </p>",
"   <p>",
"    For patients who have sustained major trauma and are undergoing CT imaging to assess for internal injury of the head, chest, or abdomen, we perform CT of the cervical spine.",
"   </p>",
"   <p>",
"    In cases of less severe trauma, the history, physical examination, and clinical decision rules are used to determine what spinal imaging is necessary. In most cases, plain radiographs (three-views) are indicated and may be preferred over CT because of decreased radiation exposure and cost. CT imaging should be obtained if abnormalities are identified on plain x-rays or suspicion for injury persists despite the absence of such abnormal findings or adequate plain x-rays cannot be obtained. CT imaging is also obtained for patients with symptoms or abnormal neurologic examination findings referable to the cervical spine.",
"   </p>",
"   <p>",
"    Both clinical decision rules (NEXUS and Canadian C-spine rule) used to determine the need for cervical spine imaging have been well studied but they must be applied appropriately. Among the patients excluded from the studies performed to develop these rules were those with direct blows to the neck, penetrating trauma, and for the Canadian C-spine rules children under 16 years. Clinicians must use clinical judgment to determine the need for imaging in these settings. Cervical spine injuries are uncommon in patients with penetrating trauma who do not manifest neurologic deficits or altered mental status, but neither clinical decision rule may be used to exclude such injuries. Spine injury in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who sustain a minor fall or collision but nevertheless are at increased risk for spinal column injury and often warrant imaging include those with severe osteoporosis, advanced arthritis, cancer, and degenerative bone disease. Imaging is prudent if disproportionate midline neck or back pain, focal spine tenderness, upper extremity paresthesias, or other suggestive symptoms are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7763589\">",
"    <span class=\"h2\">",
"     Imaging of patients not at high risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical decision rules for obtaining radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining which stable, alert trauma patients require imaging of the cervical spine can be difficult. In an effort to standardize clinical practice and guide physicians to be more selective in their use of radiographs without jeopardizing patient care, two clinical decision rules have been developed. Both the NEXUS Low-risk Criteria and the Canadian C-spine rule are well validated and sensitive, and either can be used to determine the need for cervical spine imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764600\">",
"    <span class=\"h4\">",
"     NEXUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first decision rule to be developed was the NEXUS Low-risk Criteria (NLC), which was prospectively validated in a large, multicenter, observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/18\">",
"     18",
"    </a>",
"    ]. All patients with blunt trauma who underwent radiography of the cervical spine at any of the 21 participating emergency departments were included.",
"   </p>",
"   <p>",
"    The NLC decision instrument stipulates that radiography is",
"    <strong>",
"     not",
"    </strong>",
"    necessary if patients satisfy ALL five of the following low-risk criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of posterior midline cervical tenderness",
"     </li>",
"     <li>",
"      Normal level of alertness",
"     </li>",
"     <li>",
"      No evidence of intoxication",
"     </li>",
"     <li>",
"      No abnormal neurologic findings",
"     </li>",
"     <li>",
"      No painful distracting injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insignificant injuries were defined as those that would not lead to any consequences if left undiagnosed. The NEXUS investigators evaluated 34,069 blunt trauma patients who underwent radiography of the cervical spine comprised of either a three-view cervical spine x-ray or a cervical spine computed tomography (CT) scan. Of these patients, 818 (2.4 percent) had sustained a cervical spinal column injury. Sensitivity, specificity, and negative predictive value (NPV) of the NLC were found to be 99.6 percent (95% CI 98.6-100), 12.9 percent (95% CI 12.8-13.0), and 99.9 percent (95% CI 99.8-100), respectively.",
"   </p>",
"   <p>",
"    According to the NLC researchers, examples of a \"painful distracting injury\" include long bone fractures, visceral injury requiring surgical consultation, large lacerations, crush injuries, and large burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/19\">",
"     19",
"    </a>",
"    ]. They add that an emergency clinician may categorize any injury thought \"to have the potential to impair the patient's ability to appreciate other injuries\" as a painful distracting injury.",
"   </p>",
"   <p>",
"    Some researchers believe that the presence of a painful distracting injury does not limit the accuracy of a clinical assessment of the cervical spine performed in an alert trauma patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/20\">",
"     20",
"    </a>",
"    ], but we feel such a conclusion is premature. In a study that assessed each of the NLC criteria, the authors noted that a substantial number of patients with a significant cervical spinal column injury met only one criterion, including 39 with only a distracting injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/21\">",
"     21",
"    </a>",
"    ]. In this study, the overall sensitivity of the NLC for detecting cervical injury declined to 93.5 percent when painful distracting injury was removed from the list of criteria.",
"   </p>",
"   <p>",
"    Altered level of consciousness is defined in the NLC as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow coma scale score below 15",
"     </li>",
"     <li>",
"      Disorientation to person, place, time, or events",
"     </li>",
"     <li>",
"      Inability to remember three objects at five minutes",
"     </li>",
"     <li>",
"      Delayed or inappropriate response to external stimuli",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A brief, transient loss of consciousness at the time of a motor vehicle collision does not preclude the application of the NLC, assuming the patient meets all other criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764607\">",
"    <span class=\"h4\">",
"     Canadian C-spine rule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the low specificity of NEXUS Low-risk Criteria (12.9 percent), some researchers expressed concern that use of these criteria might increase the use of radiography in some regions of the United State (US) and in the majority of countries outside of the US. These researchers subsequently developed the Canadian C-spine rule (CCR), based upon three clinical questions derived from 25 clinical variables associated with spine injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CCR involves the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Condition One: Perform radiography in patients with any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age 65 years or older",
"     </li>",
"     <li>",
"      Dangerous mechanism of injury: fall from 1 m (3 ft) or five stairs; axial load to the head, such as diving accident; motor vehicle crash at high speed (&gt;100",
"      <span class=\"nowrap\">",
"       km/hour",
"      </span>",
"      [&gt;62 mph]); motorized recreational vehicle accident; ejection from a vehicle; bicycle collision with an immovable object, such as tree or parked car",
"     </li>",
"     <li>",
"      Paresthesias in the extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Condition Two: In patients with none of the high risk characteristics listed in Condition One above, assess for any low-risk factor that allows for safe assessment of neck range of motion. The low-risk factors are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Simple rear end motor vehicle accident; excludes: pushed into oncoming traffic; hit by bus or large truck; rollover; hit by high speed (&gt;100",
"      <span class=\"nowrap\">",
"       km/hour",
"      </span>",
"      [&gt;62 mph]) vehicle",
"     </li>",
"     <li>",
"      Sitting position in emergency department",
"     </li>",
"     <li>",
"      Ambulatory at any time",
"     </li>",
"     <li>",
"      Delayed onset of neck pain",
"     </li>",
"     <li>",
"      Absence of midline cervical spine tenderness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not exhibit",
"    <strong>",
"     any",
"    </strong>",
"    of the low-risk factors listed here are",
"    <strong>",
"     NOT",
"    </strong>",
"    suitable for range of motion testing and must be assessed with radiographs.",
"   </p>",
"   <p>",
"    If a patient does exhibit",
"    <strong>",
"     any",
"    </strong>",
"    of the low-risk factors, perform range of motion testing, as described in Condition Three below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Condition Three: Test active range of motion. Perform radiography in patients who are",
"      <strong>",
"       not",
"      </strong>",
"      able to rotate their neck actively 45 degrees both left and right. Patients able to rotate their neck, regardless of pain, do not require imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the derivation study, the CCR demonstrated a sensitivity of 100 percent and a specificity of 42.5 percent for identifying clinically important cervical spine injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/22\">",
"     22",
"    </a>",
"    ]. In 2003, the CCR was prospectively studied in the emergency departments of nine Canadian tertiary care hospitals. Of 8283 patients, 162 were found to have clinically significant injuries, and the sensitivity, specificity, and negative predictive values of the CCR were respectively 99.4 percent (95% CI 96-100), 45.1 percent (95% CI 44-46), and 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/23\">",
"     23",
"    </a>",
"    ]. The investigators reported that the CCR would have missed one patient with a clinically important cervical spine injury, while the NLC would have missed 16. The CCR has also been validated in larger hospital-based studies and in an out-of-hospital study of paramedics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764614\">",
"    <span class=\"h4\">",
"     NEXUS versus Canadian C-spine rule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the NEXUS Low-risk Criteria and the Canadian C-spine rule are well validated and sensitive, and either can be used to determine the need for cervical spine imaging. Nevertheless, controversy persists about which of the two rules is more specific and more useful.",
"   </p>",
"   <p>",
"    In contrast to NEXUS, where the NLC had a sensitivity of 99.6 percent and specificity of 12.9 percent, in a subsequent Canadian study the NLC demonstrated a lower sensitivity of 90.7 percent and a higher specificity of 36.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/23\">",
"     23",
"    </a>",
"    ]. These discrepancies may stem from differences in study design. As an example, inclusion criteria differ for the two trials: the Canadian group excluded those under the age of 16 years and subjects with a Glasgow Coma Score (GCS) of less than 15, whereas these subjects were included among the NEXUS cohort. In addition, NEXUS investigators excluded all patients in whom x-rays were deemed unnecessary, while the Canadian investigators included such individuals. Thus, selection bias may account for the lower number of false negatives and true negatives reported in the Canadian study, potentially inflating both the sensitivity and specificity of the CCR. Finally, the prospective validation phase of the CCR study was performed in the same institutions in which the derivation phase was performed, raising concerns about improved performance due to familiarity with the rule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Plain x-rays versus CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe it is reasonable to use plain radiographs to assess for cervical spinal column injury in patients without a severe mechanism of injury or neurologic abnormalities, in whom adequate x-rays are likely to be obtainable, and in whom CT imaging for other potential injuries is not planned. Routine cervical spine radiographs for trauma must include anterior-posterior (AP), lateral, and odontoid (ie, open-mouth) views at a minimum. Adequate views are essential. Depending upon the patient population, up to 72 percent of plain films may be inadequate to visualize the complete cervical spine, necessitating performance of a CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/27\">",
"     27",
"    </a>",
"    ]. Once a CT is performed, plain radiographs add no further clinically relevant information and should not be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although controlled trials comparing plain radiographs to CT in elder trauma patients and others likely to have abnormal cervical anatomy (eg, advanced arthritis) have not been performed, plain x-rays can be difficult to interpret in such cases and CT may be preferable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/29\">",
"     29",
"    </a>",
"    ]. As an example, elder trauma patients are more likely to sustain type II odontoid fractures and plain films sometimes fail to provide optimal views of the atlanto-axial joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/30\">",
"     30",
"    </a>",
"    ]. As another example, distraction and rotational injuries resulting in atlanto-occipital dislocations can be difficult to diagnose with plain x-rays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition to the greater accuracy of CT in such cases, the long-term risks from increased radiation exposure are of less concern in elder patients.",
"   </p>",
"   <p>",
"    While the lateral view of the cervical spine is most helpful in diagnosing spinal injuries, it is inadequate when used alone, detecting only 60 to 80 percent of cervical spine fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Diagnostic yield increases substantially when AP and odontoid views are added. All three views must be evaluated for adequacy and the presence of abnormal findings before cervical spine immobilization is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/34\">",
"     34",
"    </a>",
"    ]. In most cases, oblique views provide no important additional information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4610880\">",
"     'Interpretation of plain radiographs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The C7 vertebra may be obscured in muscular or obese patients, as well as patients with spinal lesions that cause paralysis of the muscles that depress the shoulders. If so, the shoulders can be lowered by pulling the patient's hands toward their feet, using slow steady traction. Movement should occur only at the shoulder girdle while the head and neck remain immobilized. If this maneuver is unsuccessful or difficult to perform because of upper extremity injuries, a transaxillary (or &ldquo;swimmer's&rdquo;) view of the lower cervical vertebrae may be helpful. A CT scan is obtained if visualization of the cervical spine remains inadequate despite these additional maneuvers and views.",
"   </p>",
"   <p>",
"    The NEXUS study found that a technically adequate three-view trauma series fails to diagnose spinal injury in only 0.07 percent of patients with injuries (95% CI 0.05-0.09) and in only 0.008 percent of patients with unstable injures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, some researchers claim that too many CT studies are being performed in trauma patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/38\">",
"     38",
"    </a>",
"    ]. They emphasize the cancer risk, particularly among children, from increased radiation exposure with CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/39\">",
"     39",
"    </a>",
"    ]. Radiation is discussed further below. (See",
"    <a class=\"local\" href=\"#H7764070\">",
"     'CT for cervical spinal column injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nevertheless, the NEXUS study involved patients with minor trauma and studies in more severely injured patients suggest that plain radiographs can have limitations. According to one retrospective case series of blunt trauma patients, plain x-rays may be inadequate to visualize the complete cervical spine in up to 72 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/40\">",
"     40",
"    </a>",
"    ]. Plain radiographs, even when swimmer's and oblique views are performed, are often inadequate and may miss up to 16 percent of cervical spine fractures in severely injured, obtunded blunt trauma patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4610880\">",
"    <span class=\"h3\">",
"     Interpretation of plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If plain radiographs are used to assess the cervical spine, the clinician must be certain that the views obtained are adequate and systematically examined. On the lateral view, the entire cervical spine, from the base of the occiput to the top of the first thoracic vertebra must be clearly visible. On the odontoid view, the dens and both lateral masses must be clearly visible. Inadequate views are",
"    <strong>",
"     not",
"    </strong>",
"    acceptable.",
"   </p>",
"   <p>",
"    Once adequate views are obtained, examine each for alignment of the vertebrae; appearance, position, and spacing between vertebrae; and appearance of the soft tissues. Guides for interpreting each of the three major views (lateral, odontoid, and anterior-posterior) are provided (",
"    <a class=\"graphic graphic_figure graphicRef76687 \" href=\"mobipreview.htm?36/2/36906\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57856 \" href=\"mobipreview.htm?17/15/17657\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69613 \" href=\"mobipreview.htm?18/10/18600\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764434\">",
"    <span class=\"h2\">",
"     Imaging of patients at higher risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT imaging should ordinarily be obtained for patients involved in high-energy trauma or otherwise at significant risk of cervical spine injury, as described above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Overview of imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764070\">",
"    <span class=\"h3\">",
"     CT for cervical spinal column injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidetector computed tomography (CT) is widely used to evaluate the cervical spine in trauma patients. Practice guidelines from the Eastern Association for the Surgery of Trauma (EAST) recommend that CT from the occiput to the first thoracic vertebra, including sagittal and coronal reconstructions, be used as the primary method of screening for cervical trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of studies comparing plain radiography and CT in the detection of cervical spinal column injury following blunt trauma have found CT to be far superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. According to one review, the pooled sensitivity for detecting cervical spine injury was 52 percent for plain radiography (95% CI 47-56) while for CT it was 98 percent (95% CI 96-99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/44\">",
"     44",
"    </a>",
"    ]. Studies were included in the review if they contained data on the performance of both plain radiography and CT.",
"   </p>",
"   <p>",
"    This review is limited by several factors. Patient entry criteria varied widely among the studies, which likely contributed to the relatively high overall prevalence of cervical spinal column injury (range of 5 to 23 percent). As an example, some studies included only patients admitted to intensive care or with altered mental status. Therefore, conclusions drawn from this population, with its higher injury rate, may not apply to more typical trauma populations being screened for cervical injury. Heterogeneity tests suggest that significant differences exist among the included studies in their measurement of the sensitivity of plain radiography.",
"   </p>",
"   <p>",
"    Nevertheless, CT appears to outperform plain radiography as a screening test for patients at high risk of cervical spine injury and thus should be the initial study obtained in patients with altered mental status or severe nonspinal injury. One research group found CT to be more cost-effective than plain radiography among patients whose probability of cervical spine injury is greater than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/46\">",
"     46",
"    </a>",
"    ]. Subsequently, another group developed and validated a clinical decision rule using three injury mechanisms and three clinical parameters to identify high-risk patients that warrant imaging of the cervical spine with CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/47\">",
"     47",
"    </a>",
"    ]. The presence of any one of the following indicates high risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-speed (&ge;56 kph [35 mph] combined impact) motor vehicle crash",
"     </li>",
"     <li>",
"      Death at scene of motor vehicle crash",
"     </li>",
"     <li>",
"      Fall from height (&ge;3 m [10 ft])",
"     </li>",
"     <li>",
"      Significant closed head injury or intracranial hemorrhage seen on CT",
"     </li>",
"     <li>",
"      Neurologic symptoms or signs referred to the cervical spine",
"     </li>",
"     <li>",
"      Pelvic or multiple extremity fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is insufficient evidence to support replacing plain x-ray with CT for the initial screening of patients at lower risk for cervical spine injury. (See",
"    <a class=\"local\" href=\"#H7763589\">",
"     'Imaging of patients not at high risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to improved sensitivity in high-risk patients, CT scanning may be more efficient than plain radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A retrospective review suggests that blunt trauma patients with a normal motor examination and a normal cervical spine CT do not require further assessment with MRI before clearing the cervical spine of bony and ligamentous injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/50\">",
"     50",
"    </a>",
"    ]. CT also enables clinicians to assess for nonspinal injuries simultaneously and rapidly.",
"   </p>",
"   <p>",
"    The primary disadvantage of CT is increased radiation. Compared with conventional radiography of the cervical spine, helical CT substantially increases the mean radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/51\">",
"     51",
"    </a>",
"    ]. Researchers who precisely measured radiation exposure in 12 patients undergoing imaging of the cervical spine found a tenfold increase in the radiation dose to the skin (28 versus 2.89 mGy) and a 14-fold increase in the dose to the thyroid (26 versus 1.8 mGy) among those studied with CT compared with standard radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/52\">",
"     52",
"    </a>",
"    ]. Radiation risk generally and in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT of the cervical spine can be inadequate in some clinical settings. Images can be limited in patients with severe degenerative disease. Although CT detects 97 to 100 percent of all fractures, its accuracy in the detection of purely ligamentous injuries is not well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Evaluation for ligamentous injury and SCIWORA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CT angiography or magnetic resonance angiography is necessary to identify cerebrovascular injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/266?source=see_link\">",
"     \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764113\">",
"    <span class=\"h3\">",
"     MRI for cervical spinal column injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is less sensitive than CT for the detection of fractures of the posterior elements of the spine and injuries to the craniocervical junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/33,53\">",
"     33,53",
"    </a>",
"    ]. However, MRI is widely accepted as the imaging modality that best delineates the integrity of the spinal cord and nerve roots, intervertebral discs, surrounding soft tissue, ligamentous structures, and vertebral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/54\">",
"     54",
"    </a>",
"    ]. MRI is useful in many instances, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discriminating between neurologic deficits caused by extrinsic compression versus those caused by hemorrhage, edema, or injury to the cord itself. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnosing the causes of delayed and progressive neurologic deterioration in spinal injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link\">",
"       \"Disorders affecting the spinal cord\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detecting and predicting the outcome of &ldquo;Spinal Cord Injury Without Radiographic Abnormalities&rdquo; (SCIWORA). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation for ligamentous injury and SCIWORA'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link&amp;anchor=H20#H20\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Magnetic resonance imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determining the acuity of bony injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI and magnetic resonance arteriography (MRA) can play an important role in the assessment of vascular injury of the neck, which can be associated with cervical spine injury (eg, vertebral artery injury) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=see_link\">",
"     \"Penetrating neck injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for vascular injury of the neck is increased in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe blunt force to the neck",
"     </li>",
"     <li>",
"      Significant hyperextension or hyperflexion injuries of the neck",
"     </li>",
"     <li>",
"      Unexplained neurologic deficits",
"     </li>",
"     <li>",
"      Fractures of the skull base",
"     </li>",
"     <li>",
"      Fractures of cervical vertebra adjacent to or involving vascular foramina",
"     </li>",
"     <li>",
"      Penetrating injuries adjacent to vascular structures",
"     </li>",
"     <li>",
"      Severe facial fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its sensitivity for soft tissue injury, MRI has limitations. One important problem is the high false positive rate, which some studies suggest may be as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, debate continues about the clinical significance of many of the injuries that are detected by MRI. Other problems arise from the delays associated with MRI. When MRI is used to clear the cervical spine of soft tissue injuries, particularly in obtunded patients, these patients are subjected to prolonged spinal immobilization, which increases the risk for substantial morbidity and makes patient care more difficult. Although studies of these issues are limited, prolonged spinal immobilization is associated with an increased risk for the following problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventilator associated pneumonia and other infections",
"     </li>",
"     <li>",
"      Delirium",
"     </li>",
"     <li>",
"      Pressure ulcers of the skin",
"     </li>",
"     <li>",
"      Thromboembolism",
"     </li>",
"     <li>",
"      Difficulty with intubation and airway management",
"     </li>",
"     <li>",
"      Difficulty obtaining central venous access",
"     </li>",
"     <li>",
"      Difficult providing enteral nutrition",
"     </li>",
"     <li>",
"      Limited physical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI also brings the risks associated with the transport of sick patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/58\">",
"     58",
"    </a>",
"    ]. Ventilators, monitors, and other devices must be compatible with the MRI machine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Evaluation for ligamentous injury and SCIWORA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury without radiographic abnormality (SCIWORA) is often defined as the presence of neurologic deficits in the absence of evidence of bony injury on a complete, technically adequate, plain radiograph series or a CT scan. True SCIWORA is seldom associated with permanent neurologic injury in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/59\">",
"     59",
"    </a>",
"    ]; however, pure cervical spinal subluxation may occur when the ligamentous complexes rupture without an associated bony injury.",
"   </p>",
"   <p>",
"    Such injuries often begin posteriorly in the nuchal ligament and proceed anteriorly to involve other ligaments. The scout film of the CT scan or a plain lateral radiograph with the neck in the neutral position may show widening of both the interspinous and intervertebral spaces posteriorly. However, these findings are often subtle and can be missed. Degenerative changes of the spinal column and spinal stenosis may be risk factors for ligamentous injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7763729\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIWORA is thought by some to occur primarily in children. However, several studies published subsequent to the increased use of MRI report higher rates of SCIWORA among adults than previously suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. SCIWORA in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported rates of SCIWORA vary widely:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of the NEXUS data found that of 818 patients with cervical spine injury, 27 adult patients (3.3 percent) had SCIWORA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 166 patients with cervical spine injury sustained over a 16 year period found the rate of SCIWORA to be 4.2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/61\">",
"       61",
"      </a>",
"      ]. MRI abnormalities were identified in the majority of patients with SCIWORA.",
"     </li>",
"     <li>",
"      Another retrospective review found the prevalence of SCIWORA to be 32.2 percent among adults with a cervical spinal cord injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/60\">",
"       60",
"      </a>",
"      ]. Most SCIWORA injuries occurred in older patients and involved minor mechanisms; SCIWORA injuries in younger patients generally involved high-energy mechanisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for the discrepancies in the reported rates of SCIWORA among adults remain unclear. Increased rates may reflect a true increase in incidence or an increase in reporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Furthermore, the definition of SCIWORA varies among studies. Some define SCIWORA as any spinal cord injury not seen on plain radiograph or CT, while others believe SCIWORA should refer only to patients with a clinical spinal cord injury and no neuroimaging abnormality, including MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Approach to imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest obtaining an MRI if there is concern about a possible isolated ligamentous injury or spinal cord injury without radiographic abnormality (SCIWORA) of the cervical spine. We recommend",
"    <strong>",
"     NOT",
"    </strong>",
"    using flexion-extension studies in obtunded patients. The limitations of flexion-extension imaging are described below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Flexion-extension radiographs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    MRI can also be used to assess alert patients who may have a ligamentous injury or SCIWORA of the cervical spine. Although some experts believe that flexion-extension imaging with fluoroscopy and plain x-rays are adequate, we prefer MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/66\">",
"     66",
"    </a>",
"    ]. Clinicians should suspect a cervical ligamentous injury in an alert patient if severe neck pain, persistent midline tenderness, upper extremity paresthesias, or focal neurologic findings (eg, upper extremity weakness) are present despite a normal CT scan.",
"   </p>",
"   <p>",
"    The use of MRI for clearance following a negative CT is supported by several studies including a prospective study performed at a level one trauma center of consecutive alert patients who experienced persistent midline cervical tenderness following their initial ED evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/67\">",
"     67",
"    </a>",
"    ]. Of the 178 eligible patients, 38 were reported to have soft tissue cervical spine injuries identified by MRI that needed intervention, including five that required surgical fusion.",
"   </p>",
"   <p>",
"    In the adult patient who is obtunded or has a persistently altered mental status and whose CT and plain radiographs demonstrate no fracture, controversy exists about the best method to determine whether the cervical spine is free of unstable ligamentous injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/43,45,68-71\">",
"     43,45,68-71",
"    </a>",
"    ]. There are two possible approaches. One approach uses only a multidetector CT (MDCT) scan, and a normal result is considered sufficient to clear the cervical spine of injury. This may be a viable option if suspicion for an isolated ligamentous injury is relatively low and access to MRI is limited, or if the local radiologist has expertise reading MDCT scans of the cervical spine. The alternative approach involves obtaining an MRI to rule out soft tissue injury, even after a negative study with MDCT. Practice management guidelines from the Eastern Association for the Surgery of Trauma (EAST) state that there is insufficient evidence to make clear recommendations about how best to evaluate the cervical spine of the obtunded patient with a CT that demonstrates no fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some researchers believe that significant cervical ligamentous injuries can be missed in unconscious trauma patients and those with altered mental status unless an MRI is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/62,68,72\">",
"     62,68,72",
"    </a>",
"    ]. A meta-analysis of 11 prospective and retrospective studies found that MRI identified 182 cervical spine abnormalities, of which 96 led to substantial changes in management, among 1550 patients whose initial CT scan of the cervical spine was negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/69\">",
"     69",
"    </a>",
"    ]. When considering this review, it is important to note that no randomized trials that directly compared CT and MRI to CT alone were included, no gold standard exists against which to measure a radiologist's interpretation of CT and MRI studies, and the determination of spinal instability that requires surgery can be controversial. In addition, the sensitivity and specificity of CT for cervical spine injury continues to improve with advances in technology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other researchers believe that a normal imaging study using a contemporary MDCT scanner is sufficiently sensitive and specific to rule out any unstable injury of the cervical spine, whether bony or ligamentous. In the largest study included in the meta-analysis described above, a normal CT ruled out unstable injury in all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/70\">",
"     70",
"    </a>",
"    ]. MRI revealed four patients with a stable ligamentous injury (all were limited to a single column of the cervical spine) and seven patients with cervical cord contusions. A subsequent meta-analysis of 17 studies involving 14,327 patients assessed the effectiveness of modern multislice helical CT for detecting acute unstable cervical spine injure and reported a sensitivity and a specificity &gt;99.9 percent (95% CI 99-100 and 99-100, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/71\">",
"     71",
"    </a>",
"    ]. The authors concluded that modern CT imaging alone is sufficient to detect unstable cervical spine injuries. A subsequent review reached a similar conclusion but cautioned about the limitations of the available evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that the more recent meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/71\">",
"     71",
"    </a>",
"    ] included seven of the same studies used in the prior review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/69\">",
"     69",
"    </a>",
"    ] yet reached the opposite conclusion. Thus, the disparate conclusions may be attributable to the addition of 10 studies, involving an additional 12,777 patients, in which the prevalence of unstable cervical spine injuries was extremely low. Nevertheless, more recent studies appear to support the use of MDCT for clearance of the cervical spine in the obtunded patient.",
"   </p>",
"   <p>",
"    Performing an MRI entails risks to the unresponsive patient, including aspiration, secondary brain injury, and the increased difficulty of monitoring and performing a resuscitation in the MRI suite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/45,74,75\">",
"     45,74,75",
"    </a>",
"    ]. The financial cost of performing an MRI in all unresponsive blunt trauma patients is also substantial, particularly given that unstable injuries are uncommon in the setting of a negative CT. However, MRI does not subject the patient to ionizing radiation. The risks associated with the prolonged cervical spine immobilization are described separately. (See",
"    <a class=\"local\" href=\"#H7764113\">",
"     'MRI for cervical spinal column injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless of the method employed, clearance of the cervical spine should be performed as soon as possible (ideally within 48 hours) in obtunded patients. Prolonged use of a hard cervical collar increases the difficulty of pulmonary toilet and the risk for developing occipital decubitus ulcers. In addition, findings associated with soft tissue injury (eg, edema) may resolve if studies are delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Flexion-extension radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the obtunded patient, flexion-extension",
"    <span class=\"nowrap\">",
"     (F/E)",
"    </span>",
"    radiographs perform inadequately in the assessment of blunt cervical spine injury and we do",
"    <strong>",
"     NOT",
"    </strong>",
"    recommend their use in this circumstance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/33,45\">",
"     33,45",
"    </a>",
"    ]. In the alert and cooperative patient,",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    imaging may play a role. However, we prefer MRI if it is available.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    imaging studies have been used when concern persists about ligamentous cervical spine injury despite negative standard radiographs. Instability of the cervical spine is suggested by any of the following findings on",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    x-rays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 3.5 mm of horizontal displacement between adjacent disks",
"     </li>",
"     <li>",
"      Displaced apophyseal joints",
"     </li>",
"     <li>",
"      Widened disk spaces",
"     </li>",
"     <li>",
"      Loss of &gt;30 percent of disk height",
"     </li>",
"     <li>",
"      Prevertebral hematoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These radiographic signs of ligamentous cervical spine injury have",
"    <strong>",
"     not",
"    </strong>",
"    been prospectively validated.",
"   </p>",
"   <p>",
"    Several observational studies suggest that",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    views are inadequate for cervical spine imaging in obtunded patients with blunt trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 479",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      radiographs performed in obtunded trauma patients, researchers found over half the images obtained to be inadequate because of limited flexion or extension and poor visualization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective chart review of 123 blunt trauma victims with normal three-view plain cervical x-rays who could not be assessed clinically due to altered mental status, four of seven documented cervical spine injuries were not detected using",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      views [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/78\">",
"       78",
"      </a>",
"      ]. A comparable study of 379 patients reported that",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      imaging identified eight injuries, all of which were found to be false positives based upon subsequent MRI studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 276 patients with traumatic brain injury, dynamic",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      with fluoroscopy identified no new fractures or instability. All patients in the study underwent a protocol involving cervical spine plain radiographs, CT with three dimensional reconstructions, and",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      views. Overall,",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      views were inadequate in nine patients, truly negative in 260 of 276 patients (94 percent), falsely positive in six (2.2 percent), and falsely negative in one (0.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the alert, cooperative patient, active",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    views using fluoroscopy and still images with at least 30 degrees of excursion in each direction may be sufficient to detect occult ligamentous and disc injuries, although some question the technique&rsquo;s safety and sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. The movements are generally thought to be safe when performed slowly, as long as the patient stops any movement if pain or neurologic symptoms develop. However, the incidence of unstable cervical spine injury evident only on",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    radiographs is low and the safety of the procedure remains unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/82\">",
"     82",
"    </a>",
"    ]. Obtaining adequate views is also problematic. In one retrospective case series of 311 patients assessed with",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    imaging, only 31 percent of studies were deemed adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies assessing the use of",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    views in the alert blunt trauma patient are equivocal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subgroup analysis of the NEXUS study found that of the 818 patients found to have a cervical spine injury, 86 (10.5 percent) underwent",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      imaging. Two patients had sustained bony injuries and four patients subluxation injuries detected with",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      views, but all others had injuries apparent on routine plain radiographs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 290",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      imaging studies performed at one major trauma center found that 97 (33.5 percent) were inadequate due to limited flexion or extension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one retrospective review,",
"      <span class=\"nowrap\">",
"       F/E",
"      </span>",
"      radiographs were used to assess the presence of ligamentous cervical spine injury in 106 consecutive, awake, blunt trauma patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/86\">",
"       86",
"      </a>",
"      ]. Among patients with adequate studies, no ligamentous injuries were misdiagnosed. However, 32 patients could not flex or extend their neck sufficiently, making the studies inadequate. Of these 32 patients, four had sustained a cervical spine injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT AND DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disposition of patients with spinal column injury depends primarily upon fracture stability and concomitant injuries. If a spinal column injury is deemed unstable, hospital admission and spine surgery consultation is mandatory. If consultation is not available onsite, immediate transfer must be arranged to a center that can provide these services. Patients with unstable fractures have commonly sustained multisystem trauma, and the extent of their other injuries determines whether they require admission to an intensive care unit or other monitored setting.",
"   </p>",
"   <p>",
"    Conservative treatment of cervical fractures consists of closed reduction under fluoroscopic guidance and halo-vest immobilization. The halo is constructed of graphite or metal and is secured to the frontal and parietal areas of the skull with metal pins. The halo is the most common device applied for treatment of unstable cervical and upper thoracic fractures and dislocations as low as T3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If plain radiographs or CT demonstrate minor spinal fracture patterns and there is no neurologic deficit, then outpatient management may be possible. Isolated transverse process fractures identified by CT appear to be one example of fractures suitable for conservative management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/34/31274/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Treatment should include analgesics, and follow-up care should be arranged in all instances because even minor spinal column injuries may be associated with prolonged disability. If there is any ambiguity regarding spinal stability on plain radiographs, spine surgery consultation is warranted and a CT scan (and possibly an MRI if ligamentous injury is suspected) should be obtained.",
"   </p>",
"   <p>",
"    The management of spinal cord injury and of patients with neck pain, but no fracture or unstable soft tissue injury, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic indicators of outcome are based upon clinical presentation, associated injuries, and radiographic findings, all of which help define whether a spinal column injury is stable or unstable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PITFALLS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to immobilize the spine",
"     </li>",
"     <li>",
"      Failure to suspect spinal column injury in a multitrauma patient due to inability to evaluate neurologic deficits, or neck or back tenderness",
"     </li>",
"     <li>",
"      Accepting radiographs that are inadequate to appropriately evaluate for spinal column injury",
"     </li>",
"     <li>",
"      Failure to appreciate the high false negative rate of plain radiographs in diagnosing unstable burst fractures; failure to obtain a CT scan in such cases",
"     </li>",
"     <li>",
"      Failure to radiograph the entire spine when a fracture at one spinal level is demonstrated",
"     </li>",
"     <li>",
"      Failure to obtain specialty consultation when there is a fracture, instability, or neurologic deficits",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/0/15363?source=see_link\">",
"       \"Patient information: Neck fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspect a spinal column injury in any trauma victim, especially in the setting of motor vehicle collisions, assaults, falls, and sports-related injuries. Spinal immobilization, including backboard, rigid cervical collar, and lateral head supports for transport, should be initiated at the scene, and immobilization should be maintained until an unstable spinal injury is excluded. Techniques for safe helmet removal are described above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prehospital management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The priorities of trauma management do not change in the setting of potential spinal column injury. Anticipate airway management problems in patients with cervical spinal column injury. Unstable lesions above C3 may cause immediate respiratory paralysis and lower cervical lesions may cause delayed respiratory distress. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Emergency department (ED) management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of spinal cord injury is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have sustained major trauma or are otherwise at high risk for cervical spinal column injury, we suggest performing a CT scan of the entire cervical spine. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Overview of imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7764070\">",
"       'CT for cervical spinal column injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the obtunded adult patient, we suggest that flexion-extension imaging",
"      <strong>",
"       NOT",
"      </strong>",
"      be used to assess for a possible isolated ligamentous injury or SCIWORA of the cervical spine. We suggest using MRI to perform this assessment, if it is considered necessary. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation for ligamentous injury and SCIWORA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Flexion-extension radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of less severe trauma, the history, physical examination, and clinical decision rules are used to determine if spinal imaging is necessary. Both the NEXUS Low-risk Criteria and the Canadian C-spine rule are well validated and sensitive. We suggest that either the NEXUS Low-risk Criteria or the Canadian C-spine rule be used to determine the need for cervical spine imaging in appropriate patients. The characteristics and implementation of each rule are discussed above. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical decision rules for obtaining radiographs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12520?source=see_link&amp;anchor=H7762768#H7762768\">",
"       \"Evaluation of thoracic and lumbar spinal column injury\", section on 'Decision rules for imaging thoracic or lumbar spine injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We believe either plain x-rays or CT are acceptable to screen patients without a severe mechanism of injury, neurologic abnormalities, or concerning examination findings who are otherwise at low risk for cervical spinal column injury. Selection of the appropriate study depends upon a number of factors, including: clinician judgment; hospital resources; and patient age, size, and comorbidities (eg, degenerative osteoarthritis). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Overview of imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Plain x-rays versus CT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1476602\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/1\">",
"      Rhee P, Kuncir EJ, Johnson L, et al. Cervical spine injury is highly dependent on the mechanism of injury following blunt and penetrating assault. J Trauma 2006; 61:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/2\">",
"      Salim A, Martin M, Sangthong B, et al. Near-hanging injuries: a 10-year experience. Injury 2006; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/3\">",
"      Hanna SJ. A study of 13 cases of near-hanging presenting to an Accident and Emergency Department. Injury 2004; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     www.facs.org/trauma/publications/helmet.pdf www.facs.org/trauma/publications/helmet.pdf (Accessed on February 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/5\">",
"      Crosby ET. Airway management in adults after cervical spine trauma. Anesthesiology 2006; 104:1293.",
"     </a>",
"    </li>",
"    <li>",
"     Advanced trauma life support student course manual, 7th ed, American College of Surgeons 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/7\">",
"      Ollerton JE, Parr MJ, Harrison K, et al. Potential cervical spine injury and difficult airway management for emergency intubation of trauma adults in the emergency department--a systematic review. Emerg Med J 2006; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/8\">",
"      Manoach S, Paladino L. Manual in-line stabilization for acute airway management of suspected cervical spine injury: historical review and current questions. Ann Emerg Med 2007; 50:236.",
"     </a>",
"    </li>",
"    <li>",
"     Tator, CH. Management of associated spine injures in head injured patients. In: Neurotrauma, Narayan, RK, Wilberger, JE, Poulishock, JT (Eds), McGraw-Hill, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/10\">",
"      Hackl W, Hausberger K, Sailer R, et al. Prevalence of cervical spine injuries in patients with facial trauma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/11\">",
"      Williams J, Jehle D, Cottington E, Shufflebarger C. Head, facial, and clavicular trauma as a predictor of cervical-spine injury. Ann Emerg Med 1992; 21:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/12\">",
"      Holly LT, Kelly DF, Counelis GJ, et al. Cervical spine trauma associated with moderate and severe head injury: incidence, risk factors, and injury characteristics. J Neurosurg 2002; 96:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/13\">",
"      Maroon JC, Abla AA. Classification of acute spinal cord injury, neurological evaluation, and neurosurgical considerations. Crit Care Clin 1987; 3:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/14\">",
"      Esposito TJ, Ingraham A, Luchette FA, et al. Reasons to omit digital rectal exam in trauma patients: no fingers, no rectum, no useful additional information. J Trauma 2005; 59:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/15\">",
"      Porter JM, Ursic CM. Digital rectal examination for trauma: does every patient need one? Am Surg 2001; 67:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/16\">",
"      Shlamovitz GZ, Mower WR, Bergman J, et al. Poor test characteristics for the digital rectal examination in trauma patients. Ann Emerg Med 2007; 50:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/17\">",
"      Guldner GT, Brzenski AB. The sensitivity and specificity of the digital rectal examination for detecting spinal cord injury in adult patients with blunt trauma. Am J Emerg Med 2006; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/18\">",
"      Hoffman JR, Mower WR, Wolfson AB, et al. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. N Engl J Med 2000; 343:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/19\">",
"      Hoffman JR, Wolfson AB, Todd K, Mower WR. Selective cervical spine radiography in blunt trauma: methodology of the National Emergency X-Radiography Utilization Study (NEXUS). Ann Emerg Med 1998; 32:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/20\">",
"      Rose MK, Rosal LM, Gonzalez RP, et al. Clinical clearance of the cervical spine in patients with distracting injuries: It is time to dispel the myth. J Trauma 2012; 73:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/21\">",
"      Panacek EA, Mower WR, Holmes JF, et al. Test performance of the individual NEXUS low-risk clinical screening criteria for cervical spine injury. Ann Emerg Med 2001; 38:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/22\">",
"      Stiell IG, Wells GA, Vandemheen KL, et al. The Canadian C-spine rule for radiography in alert and stable trauma patients. JAMA 2001; 286:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/23\">",
"      Stiell IG, Clement CM, McKnight RD, et al. The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. N Engl J Med 2003; 349:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/24\">",
"      Vaillancourt C, Stiell IG, Beaudoin T, et al. The out-of-hospital validation of the Canadian C-Spine Rule by paramedics. Ann Emerg Med 2009; 54:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/25\">",
"      Stiell IG, Clement CM, Grimshaw J, et al. Implementation of the Canadian C-Spine Rule: prospective 12 centre cluster randomised trial. BMJ 2009; 339:b4146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/26\">",
"      Yealy DM, Auble TE. Choosing between clinical prediction rules. N Engl J Med 2003; 349:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/27\">",
"      Gale SC, Gracias VH, Reilly PM, Schwab CW. The inefficiency of plain radiography to evaluate the cervical spine after blunt trauma. J Trauma 2005; 59:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/28\">",
"      Mathen R, Inaba K, Munera F, et al. Prospective evaluation of multislice computed tomography versus plain radiographic cervical spine clearance in trauma patients. J Trauma 2007; 62:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/29\">",
"      Greenbaum J, Walters N, Levy PD. An evidenced-based approach to radiographic assessment of cervical spine injuries in the emergency department. J Emerg Med 2009; 36:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/30\">",
"      Watanabe M, Sakai D, Yamamoto Y, et al. Upper cervical spine injuries: age-specific clinical features. J Orthop Sci 2010; 15:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/31\">",
"      Govender S, Vlok GJ, Fisher-Jeffes N, Du Preez CP. Traumatic dislocation of the atlanto-occipital joint. J Bone Joint Surg Br 2003; 85:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/32\">",
"      West OC, Anbari MM, Pilgram TK, Wilson AJ. Acute cervical spine trauma: diagnostic performance of single-view versus three-view radiographic screening. Radiology 1997; 204:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/33\">",
"      Crim JR, Moore K, Brodke D. Clearance of the cervical spine in multitrauma patients: the role of advanced imaging. Semin Ultrasound CT MR 2001; 22:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/34\">",
"      Petri R, Gimbel R. Evaluation of the patient with spinal trauma and back pain: an evidence based approach. Emerg Med Clin North Am 1999; 17:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/35\">",
"      Freemyer B, Knopp R, Piche J, et al. Comparison of five-view and three-view cervical spine series in the evaluation of patients with cervical trauma. Ann Emerg Med 1989; 18:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/36\">",
"      Offerman SR, Holmes JF, Katzberg RX, Richards JR. Utility of supine oblique radiographs in detecting cervical spine injury. J Emerg Med 2006; 30:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/37\">",
"      Mower WR, Hoffman JR, Pollack CV Jr, et al. Use of plain radiography to screen for cervical spine injuries. Ann Emerg Med 2001; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/38\">",
"      Kaups KL, Davis JW, Parks SN. Routinely repeated computed tomography after blunt head trauma: does it benefit patients? J Trauma 2004; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/39\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/40\">",
"      Gale SC, Gracias VH, Reilly PM, Schwab CW. The inefficiency of plain radiography to evaluate the cervical spine after blunt trauma. J Trauma 2005; 59:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/41\">",
"      Widder S, Doig C, Burrowes P, et al. Prospective evaluation of computed tomographic scanning for the spinal clearance of obtunded trauma patients: preliminary results. J Trauma 2004; 56:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/42\">",
"      Ajani AE, Cooper DJ, Scheinkestel CD, et al. Optimal assessment of cervical spine trauma in critically ill patients: a prospective evaluation. Anaesth Intensive Care 1998; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/43\">",
"      Como JJ, Diaz JJ, Dunham CM, et al. Practice management guidelines for identification of cervical spine injuries following trauma: update from the eastern association for the surgery of trauma practice management guidelines committee. J Trauma 2009; 67:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/44\">",
"      Holmes JF, Akkinepalli R. Computed tomography versus plain radiography to screen for cervical spine injury: a meta-analysis. J Trauma 2005; 58:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/45\">",
"      Plumb JO, Morris CG. Clinical review: Spinal imaging for the adult obtunded blunt trauma patient: update from 2004. Intensive Care Med 2012; 38:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/46\">",
"      Blackmore CC, Ramsey SD, Mann FA, Deyo RA. Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. Radiology 1999; 212:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/47\">",
"      Hanson JA, Blackmore CC, Mann FA, Wilson AJ. Cervical spine injury: a clinical decision rule to identify high-risk patients for helical CT screening. AJR Am J Roentgenol 2000; 174:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/48\">",
"      Daffner RH. Cervical radiography for trauma patients: a time-effective technique? AJR Am J Roentgenol 2000; 175:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/49\">",
"      Daffner RH. Helical CT of the cervical spine for trauma patients: a time study. AJR Am J Roentgenol 2001; 177:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/50\">",
"      Schuster R, Waxman K, Sanchez B, et al. Magnetic resonance imaging is not needed to clear cervical spines in blunt trauma patients with normal computed tomographic results and no motor deficits. Arch Surg 2005; 140:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/51\">",
"      Adelgais KM, Grossman DC, Langer SG, Mann FA. Use of helical computed tomography for imaging the pediatric cervical spine. Acad Emerg Med 2004; 11:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/52\">",
"      Rybicki F, Nawfel RD, Judy PF, et al. Skin and thyroid dosimetry in cervical spine screening: two methods for evaluation and a comparison between a helical CT and radiographic trauma series. AJR Am J Roentgenol 2002; 179:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/53\">",
"      Holmes JF, Mirvis SE, Panacek EA, et al. Variability in computed tomography and magnetic resonance imaging in patients with cervical spine injuries. J Trauma 2002; 53:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/54\">",
"      Cohen WA, Giauque AP, Hallam DK, et al. Evidence-based approach to use of MR imaging in acute spinal trauma. Eur J Radiol 2003; 48:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/55\">",
"      Cothren CC, Moore EE, Biffl WL, et al. Cervical spine fracture patterns predictive of blunt vertebral artery injury. J Trauma 2003; 55:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/56\">",
"      Biffl WL, Moore EE, Offner PJ, Burch JM. Blunt carotid and vertebral arterial injuries. World J Surg 2001; 25:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/57\">",
"      Malhotra AK, Camacho M, Ivatury RR, et al. Computed tomographic angiography for the diagnosis of blunt carotid/vertebral artery injury: a note of caution. Ann Surg 2007; 246:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/58\">",
"      Cooper DJ, Ackland HM. Clearing the cervical spine in unconscious head injured patients - the evidence. Crit Care Resusc 2005; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/59\">",
"      Kothari P, Freeman B, Grevitt M, Kerslake R. Injury to the spinal cord without radiological abnormality (SCIWORA) in adults. J Bone Joint Surg Br 2000; 82:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/60\">",
"      Kato H, Kimura A, Sasaki R, et al. Cervical spinal cord injury without bony injury: a multicenter retrospective study of emergency and critical care centers in Japan. J Trauma 2008; 65:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/61\">",
"      Kasimatis GB, Panagiotopoulos E, Megas P, et al. The adult spinal cord injury without radiographic abnormalities syndrome: magnetic resonance imaging and clinical findings in adults with spinal cord injuries having normal radiographs and computed tomography studies. J Trauma 2008; 65:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/62\">",
"      Tewari MK, Gifti DS, Singh P, et al. Diagnosis and prognostication of adult spinal cord injury without radiographic abnormality using magnetic resonance imaging: analysis of 40 patients. Surg Neurol 2005; 63:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/63\">",
"      Hendey GW, Wolfson AB, Mower WR, et al. Spinal cord injury without radiographic abnormality: results of the National Emergency X-Radiography Utilization Study in blunt cervical trauma. J Trauma 2002; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/64\">",
"      Yucesoy K, Yuksel KZ. SCIWORA in MRI era. Clin Neurol Neurosurg 2008; 110:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/65\">",
"      Gupta SK, Rajeev K, Khosla VK, et al. Spinal cord injury without radiographic abnormality in adults. Spinal Cord 1999; 37:726.",
"     </a>",
"    </li>",
"    <li>",
"     Determination of Cervical Spine Stability in Trauma Patients www.east.org/tpg/chap3u.pdf (Accessed on June 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/67\">",
"      Ackland HM, Cameron PA, Varma DK, et al. Cervical spine magnetic resonance imaging in alert, neurologically intact trauma patients with persistent midline tenderness and negative computed tomography results. Ann Emerg Med 2011; 58:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/68\">",
"      Menaker J, Philp A, Boswell S, Scalea TM. Computed tomography alone for cervical spine clearance in the unreliable patient--are we there yet? J Trauma 2008; 64:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/69\">",
"      Schoenfeld AJ, Bono CM, McGuire KJ, et al. Computed tomography alone versus computed tomography and magnetic resonance imaging in the identification of occult injuries to the cervical spine: a meta-analysis. J Trauma 2010; 68:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/70\">",
"      Hogan GJ, Mirvis SE, Shanmuganathan K, Scalea TM. Exclusion of unstable cervical spine injury in obtunded patients with blunt trauma: is MR imaging needed when multi-detector row CT findings are normal? Radiology 2005; 237:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/71\">",
"      Panczykowski DM, Tomycz ND, Okonkwo DO. Comparative effectiveness of using computed tomography alone to exclude cervical spine injuries in obtunded or intubated patients: meta-analysis of 14,327 patients with blunt trauma. J Neurosurg 2011; 115:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/72\">",
"      Stassen NA, Williams VA, Gestring ML, et al. Magnetic resonance imaging in combination with helical computed tomography provides a safe and efficient method of cervical spine clearance in the obtunded trauma patient. J Trauma 2006; 60:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/73\">",
"      Kirschner J, Seupaul RA. Does computed tomography rule out clinically significant cervical spine injuries in obtunded or intubated blunt trauma patients? [corrected]. Ann Emerg Med 2012; 60:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/74\">",
"      Dunham CM, Brocker BP, Collier BD, Gemmel DJ. Risks associated with magnetic resonance imaging and cervical collar in comatose, blunt trauma patients with negative comprehensive cervical spine computed tomography and no apparent spinal deficit. Crit Care 2008; 12:R89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/75\">",
"      Como JJ, Thompson MA, Anderson JS, et al. Is magnetic resonance imaging essential in clearing the cervical spine in obtunded patients with blunt trauma? J Trauma 2007; 63:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/76\">",
"      Bagley LJ. Imaging of spinal trauma. Radiol Clin North Am 2006; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/77\">",
"      Griffiths HJ, Wagner J, Anglen J, et al. The use of forced flexion/extension views in the obtunded trauma patient. Skeletal Radiol 2002; 31:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/78\">",
"      Freedman I, van Gelderen D, Cooper DJ, et al. Cervical spine assessment in the unconscious trauma patient: a major trauma service's experience with passive flexion-extension radiography. J Trauma 2005; 58:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/79\">",
"      Goodnight TJ, Helmer SD, Dort JM, et al. A comparison of flexion and extension radiographs with computed tomography of the cervical spine in blunt trauma. Am Surg 2008; 74:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/80\">",
"      Padayachee L, Cooper DJ, Irons S, et al. Cervical spine clearance in unconscious traumatic brain injury patients: dynamic flexion-extension fluoroscopy versus computed tomography with three-dimensional reconstruction. J Trauma 2006; 60:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/81\">",
"      Harrison JL, Ostlere SJ. Diagnosing purely ligamentous injuries of the cervical spine in the unconscious trauma patient. Br J Radiol 2004; 77:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/82\">",
"      Sliker CW, Mirvis SE, Shanmuganathan K. Assessing cervical spine stability in obtunded blunt trauma patients: review of medical literature. Radiology 2005; 234:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/83\">",
"      Khan SN, Erickson G, Sena MJ, Gupta MC. Use of flexion and extension radiographs of the cervical spine to rule out acute instability in patients with negative computed tomography scans. J Orthop Trauma 2011; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/84\">",
"      Pollack CV Jr, Hendey GW, Martin DR, et al. Use of flexion-extension radiographs of the cervical spine in blunt trauma. Ann Emerg Med 2001; 38:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/85\">",
"      Wang JC, Hatch JD, Sandhu HS, Delamarter RB. Cervical flexion and extension radiographs in acutely injured patients. Clin Orthop Relat Res 1999; :111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/86\">",
"      Insko EK, Gracias VH, Gupta R, et al. Utility of flexion and extension radiographs of the cervical spine in the acute evaluation of blunt trauma. J Trauma 2002; 53:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/87\">",
"      Botte MJ, Byrne TP, Abrams RA, Garfin SR. Halo Skeletal Fixation: Techniques of Application and Prevention of Complications. J Am Acad Orthop Surg 1996; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/88\">",
"      Bradley LH, Paullus WC, Howe J, Litofsky NS. Isolated transverse process fractures: spine service management not needed. J Trauma 2008; 65:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/34/31274/abstract/89\">",
"      Homnick A, Lavery R, Nicastro O, et al. Isolated thoracolumbar transverse process fractures: call physical therapy, not spine. J Trauma 2007; 63:1292.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 342 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31274=[""].join("\n");
var outline_f30_34_31274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7764673\">",
"      EPIDEMIOLOGY AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3417199\">",
"      MECHANISMS, CLASSIFICATION SCHEMES, AND TYPES OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prehospital management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Spinal immobilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Helmet removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Emergency department (ED) management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Airway management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spinal and neurogenic shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Secondary survey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RADIOGRAPHIC EVALUATION OF CERVICAL SPINAL COLUMN INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview of imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7763589\">",
"      Imaging of patients not at high risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical decision rules for obtaining radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7764600\">",
"      NEXUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7764607\">",
"      Canadian C-spine rule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7764614\">",
"      NEXUS versus Canadian C-spine rule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Plain x-rays versus CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4610880\">",
"      - Interpretation of plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7764434\">",
"      Imaging of patients at higher risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7764070\">",
"      - CT for cervical spinal column injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7764113\">",
"      - MRI for cervical spinal column injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Evaluation for ligamentous injury and SCIWORA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7763729\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Approach to imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Flexion-extension radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DEFINITIVE MANAGEMENT AND DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1476602\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/342|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/15/17657\" title=\"diagnostic image 1\">",
"      Guide for odontoid cervical spine x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/10/18600\" title=\"diagnostic image 2\">",
"      Guide for AP cervical spine x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/342|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/2/36906\" title=\"figure 1\">",
"      Guide for lateral cervical spine x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/28/33228\" title=\"table 1\">",
"      Spine injury classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/266?source=related_link\">",
"      Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12520?source=related_link\">",
"      Evaluation of thoracic and lumbar spinal column injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15815?source=related_link\">",
"      Field care and evaluation of the young athlete with acute neck injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23689?source=related_link\">",
"      Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/0/15363?source=related_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23113?source=related_link\">",
"      Treatment of neck pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_34_31275="Valve surgery congenital MR";
var content_f30_34_31275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in adolescents or young adults with congenital mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement mitral valve surgery is indicated in adolescents or young adults with congenital MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Symptomatic severe MR with NYHA class III-IV symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Asymptomatic severe MR and left ventricular dysfunction, defined as a left ventricular ejection fraction (LVEF) &le;60 mmHg.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Mitral valve repair in experienced surgical centers in asymptomatic severe MR and preserved left ventricular function (LVEF &gt;60 percent) if the estimated likelihood of successful repair without residual MR is greater than 90 percent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Asymptomatic severe and preserved left ventricular function (LVEF &gt;60 percent) if valve replacement is highly likely.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31275=[""].join("\n");
var outline_f30_34_31275=null;
var title_f30_34_31276="Definitions of LD";
var content_f30_34_31276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of learning disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        US Office of Education",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The term \"specific learning disability\" means a disorder in one or more basic psychological processes involved in understanding or in using language, spoken or written, which may manifest itself in an imperfect ability to listen, speak, read, write, spell, or do mathematical calculations. The term includes such conditions as perceptual handicaps, brain injury, minimal brain dysfunction, dyslexia, and developmental aphasia. Such terms do not include children who have learning disabilities which are primarily the result of visual, hearing, or motor handicaps, of mental retardation, of emotional disturbance, or of environmental, cultural, or economic disadvantage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        DSM IV TR",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Reading, writing, or math achievement, as measured by individually administered standardized tests of reading accuracy, reading comprehension, writing, or math, are substantially below that expected given the person's chronological age, measured intelligence, and age-appropriate education.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. The disturbance significantly interferes with academic achievement or activities of daily living that require reading skills, the composition of written texts, or mathematical ability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. If a sensory deficit is present, the reading, writing, or math difficulties are in excess of those usually associated with it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Joint Commission on Learning Disabilities",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Learning disabilities is a general term that refers to a heterogeneous group of disorders manifested by significant difficulties in the acquisition and use of listening, speaking, reading, writing, reasoning, or mathematical skills.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These disorders are intrinsic to the individual, presumed to be due to central nervous system dysfunction, and may occur across the life span. Problems in self-regulatory behaviors, social perception, and social interaction may exist with learning disabilities but do not, by themselves, constitute a learning disability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Although learning disabilities may occur concomitantly with other disabilities (eg, sensory impairment, mental retardation, serious emotional disturbance), or with extrinsic influences (such as cultural differences, insufficient or inappropriate instruction), they are not the result of those conditions or influences.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. United States Office of Education. Definition and criteria for defining students as learning disabled. Federal Register, 42:250, US Government Printing Office, Washington, DC, 1977. p.65083.",
"     <br>",
"      2. Learning Disorders. In: Diagnostic and Statistical Manual - Text Revision (DSM-IV-TR, 2000), 4th ed, First ME (Ed), American Psychiatric Association, Washington, DC, 2000",
"      <br>",
"       3. National Joint Committee on Learning Disabilities (NJCLD). Operationalizing the NJCLD definition of learning disabilities for ongoing assessment in schools. American Speech-Language Hearing Association 1997. Available at: www.asha.org/docs/html/RP1998-00130.html. Accessed on February 17, 2010.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31276=[""].join("\n");
var outline_f30_34_31276=null;
var title_f30_34_31277="Probability of ovulation";
var content_f30_34_31277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Probability of ovulation relative to midpoint of the cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 248px; background-image: url(data:image/gif;base64,R0lGODlhxwH4AMQAAP////8AAAAzmSBzOYCAgP+ZMwAAAAAZTH8AAMDAwBA5HEBAQH9MGX9/f6CgoDAwMCAgIODg4PDw8BAQEFBQUNDQ0LCwsJCQkHBwcGBgYAgcDj8/PwAMJj8mDD8AAAAAACH5BAAAAAAALAAAAADHAfgAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMSRUXBA4SIgmVlY2YmZoABp0GCyKenZukpYUOABGjnAaWpq+wfQkYBgShnxQJsbu8dA4LBhgiFAQZBhMRJQkEzM3Mur3R0lzA0CLVys7NC7bT3t9PCQ8EtAYR4sXHkyzM4O7vRxEPnRAWqfMGDxUu7fD+/1j6ARxI0InAgggTEjmosKFDHQwfSpwIIyLFixhNWMzI8eLGjiAdfgxJsuDIkjse/0VaJ8HByhMSEiRDKeckTRyiQAGYB+yBiQQUat2MY3NoDVSqDACwYIACgKD2SHjqZrRN0aozZgklsFVoCa5Usaq5KhbGr2AAwKb1SkJt2bFh3+qodgEtrQsa2co1Q3ZvCnTlIqiCkACCOQDAKBnLYM3vmL6OTcijF9WBYQioECtl5SkyGcieQ/cBLbq0F5WSRLR82YK06ddZcorgmY9fXNi4xyAdxdQp1Na3YS/TRry48ePPcuvQakut2xHDtXFTPoKABwTYs2vfzr27dw/Bqcc4K8y5XgDRnU0XTwBBgPfw48ufT78+gvDiY9C1awAvO/yltVffgAQOeF9+NADWif9gBhBm2EwruCaWgAVWWOGBCMowWYOVXZbZf/lRaOGI9GGY4RISYiUiiSy+Z+KJSaRY1YotkvgijEfIaBSNNVp4I45F6DgUjz0W+COQQwh5E5FFGgggkj4oSROTTZb4JJQ8SIkSlVXKdySWP2hZEpddwvclmD2ISRKZZQZwJpo7qBkSm2W+CWcOcoJEZ5d23nlDnh3tWWWfftYAKEeCNklooTMcmlGiRS7KaAyOYgRpj5JO+kKlHrnXJoGZagpciJ5+at+VWEYAyQXrWHLJqOyVaup8ocIITCc+cbYKiLHOeqqoIlgggQSG6dKJK7BSd2mNtQL5ICsL5GIbqb5aCez/CHUJ81Q6yGRD3HrKylqti6hiSUsGJmBDQnrblOvYsi02m2FQEDyDjjETrBOhu37By6K8CIpSy4b6TNvruPEBfO1X/O7lr40NL4wCpxQ9PKLCEotA8UQW+xhxxgxTi7CZH4NcXckTijsuxhlvLFHHF6JssssPwWykzCDTLJLK1bIssc4N2Qwqzi0TPSTPvvq8MNAKCe2kyYYavSTSsyp9LdMJOf0r1I1KPSXVploNLNYIaW0t1zKQbRLYn4otqtqFJLCPai6xikIl+kbIdptuawq3IBVwpZMEtOVrggPH8rN3nV7DpioBdgOwWmrJPnSrTgnUpu4IEUyQeGuL89n4/2u31rbTJ6bzOlHmg8/zAATolrDA7K0oPjLJ1wpLbCu9PWVAVPtexLpqGUxg2AN5X4DM5nrfTm7GD5oXF7vMgCvR8ADUZUtQYZX+efPO9/1atms1dx71BFjv0CP5JNBS+/OgklgFlcwTOfi3i1/auSKQf1flDvGeLjDguXpdYzMHbIwKzEar0ZmGXs8YTGEOozrlMNBLDiyNwGxhmQZ9KHgHy18GGfU3gFwwYSMsVAn/cULcoY1SKURU6AYVwzut8A7oQ44OkaPAFj7vhRWp4SEIwIEDGPGISEyiEpfIRA7ExYduEiKabmgHAhxAAFjMoha3yMUuevEAT5yhoqQIJv8q1sGKXkyjGtMIxq+IMVJkxJIZ6YDGNdrRjm1syxsxFUcozXEOdbyjILuYx+rskVl9RNIfa3LFQTpSi4XU2CHjlUggLZIojXzkIyOZlkn+q5I4uiQcAqnJQXISivpTISj/QMpS3vGUnoQYEINYtky68pVhdF4UZ7mpVfqhlbdUIyx1mUo/ifINwAzmF3MZPl9m6JhuSKYyuTjMZkpMbtBxlcEIIs1pQpKZIrxW4D4xAoFtcyDd9CYWqxlOYF2unK14VQVNaEt1UhOcIyumZ7AHLWkBkIX1tOc33UhMZw6Fn8TAF4QoURz1AVSgyySoNa/FzxEwDz0NNWgWsCmCx93/jwQxWegCAwpRAbAznxpFCfse4L57qeOfgBinTjSDq59wjx8khehJEaZPxwiQYHObZyDeGaxhFasEU8FpSe8p0XaygKPQCSoJHidVOabUChUVwbO+cp4UpFOdO13ZlWQ6ArKWoAITMN7v4ARNJWSVfHkp11e9GdaeXYmoNJ3pCKAyGLZetQoV5d8JnhOhnAq0rklDVUWzqhl77Mqqhlip+3xXLwLoIjHoWYwCJ2ZYeyK2aoolJ3RESwLETeBWfjWEAHUlFMyakx2dBSs+eRpavTJ2KZEgLWRNElu6zlasLJDsJISrmVRYwALzAN5uudnbaX42bHcVxWWlW9zM5UO5/8tFZ3OV+dy2/TU3bWXDXJ37W7vy8px5yOEO16uNHm43mN3l23dxE94oaUAB+M2vfvfL3/76VwNPfO8t48u488K0igoYgIIXzOAGO/jBEFZAgJe6RQKLzlvszXBxNgve+SKBAAmGsIhHHOEJUziLFqbhV4rIxBa7uIkehkd90xRiEtuYxBL+ioBdmeIx6vjEKI7xO2acpRrf+MgOznFbdlzKHsPxx0A2qZDdQeQ4GRnJWB6AkqvDZE06mY9QBjInLTjlhVw5y0fessa6vMnyJjbMJx5zh0dzZjTbWM1pYbMjv4xIOFNYziSB6uTytsAyJ6nOdh4xnsfLXTeD1s9LBf90R8x6up6glwur+WijEJ3oEkO6pHym5Kd1amhCELV3vxGqFgiHOsMZitOdTrKJxexo6I76sKUmBPakh2H15Hq0PrkopWAdawYvWs+mrLV3b+3ZXwti112ZXkbBwOrXxe7Vxb7xsaMs5aailNmyNQr2/NefA2NBAsU7HqGHne07zzrOypYvuH07FOFKcKsg9IL2fCczELcbx+/+c7wLvGRuS5ojq+0gZi6tBcSxNH428Pe/RbztKIf6k/Mm7zOdLQICNghnEp/4gytOa2/TNuON3jidRe7pglt84Bd2eckRVGWIELvdJIe3yYErc53TnOM0ZvnIAx5pmKu45wJXeTj/NMz09n7l5tnOedL1WFCUwxfou4AbATrAgK57/etgD7vYx96BJ0K92FIv+s7Ni3S1/xwKBGBAAeZO97rb/e54zzsDzC50WVt9wEb3cdtBzS9XcfhxH3yURuOe98Y7vvF7f3rfG5x2wq/9zYMnNQxeW9pjRGtOi5f740c/+si35eyxrrzmqT5RLhucX8eSZ0cbtG7Fw130pM893k1fHdR3WvW4vvyjMx/8F3QiWgqsywM8559AhV730Lc77zXm+0QDv9nCtzXxsf+ChB5joVzJgAU8J1KPPD/66J9+Wqpv5+uHm/VOXfPrZ8C8fQu7YudHP/TVH/LJa5nolgd/37Z9/+/XAi5lOOQ0GOPnaoiSf/qXe/zHfmjmfvQmgCdHgBXYAkAVCjqhcFVlKQ74gKXHd/6nYBSocRbIc673ckpnELgngiMoeSX4f3/HY4H3ZBiIgiESgjAIeSRYgieYcinIdis4c2VheAwXIy/Ygz4og0AIgKtnSFWXg0IIHU13hZbFC5yXb03AeEz4eBE4gzRIhVeXfctGhoD3FfflX2zYhv+FdVcQexw2WDz4hdL3g/4XhGU4hJhXhD7Xe2KIZ6ZwfP6kakpoh44XhjOoh2nIh8Pnh1MHiIsIh1bgfd2yLtP2BF6IiLuHh5PHiDZohvKGhqF4eoHYMB5Ve+gxWXpwUf/o41BKsImceIdOmIdQWHxS2Hryx4KmOIn64Qm5UgKIUzt2cICqGDKauISzOHeK+IQ12GQ3CGakCI21+IkNoztHNVWeQ4x1sIHmliPKuIzNaIvP6GXR2GfTaI7V2HeC6AL4dg20M4eDoHXhOIvjaI3l2GaiSHCQ6HaS6IwyAFfYsjzciAj0uIx3d4/seIvcl4vxl2fz14sACQOCRQLeU5CGcJAIWXcKKXSgSI2OqH39GID/SI4wAEFZSE70Iw79cYyBoJEbyYyeuJD5uGfnKGrpqI8SaZLGJwq2oFv3RwgwGZMdyXIfqY4heYYjGYXUd4pfMGiSAQkfGBDuApXegl3/rVGPnFiUIneUOumQA7iUuNiUvugFtBGMIoBWaoWVV0AWZ6kMPkkpWomIXDlxXmmT+xhzYtmQZDmRW4Bqa7VXv9NXXHAVgKlc5wAAiKNXWRmTdFeX/3aXyZaXR7eXBdiXPLkFvGZRa/VYWXAVm1laFDABbLlAc2mHkIlzDHmZnTSFlpmBmImPmIiFTCePExNtnXdankmV/ICbJYABy5d47HCaX5iaUbeasNmaugiRvFiSslkdXDd20jmdZNcw5NZ8wZJbjMmbLXCdKLCbEUKcTGicaIecOihJrrmLRhibNNkW4tmD6scC93YYCXhcydUFVzGfyUBOBEAM9CKXjimT/+vokeZZhei5nIy2h87ZntXxnjAYnyygcJlBTtb1AKVpBWQhoRy4FIbxCVNpmgFaAOSZegWqoAf6kAnaiAtKoF/hoCIIoXgwlBs5or9Xoip6omGpnn/InizqniEKo3cgowhJo9Zno6UIlhf4mue5fk7powEKpFVUh/Y4kz2qpAaqnCiKbIJ0ShKYZYvmog8IpWckpVtJpUZppCCJpCqoo5HIo2faoj8qbbSpYbb5YVShXnO6YXD6pGbalWiKlGpKhGzqj27qp3vqmPy3AQ2wqIzaqI76qJAaqRuQQVapOgSgqJGaqZoqqU8EpvpHpO33p1+Jo0k6qCRZqHbZqXH6Ff8NQAQNkEFvmSwE0KpD8KqHSpR9mqo1OZlJOYpWaqJMWpYNuqptQatCYKs9cJiyaqxBgKzDyqcD+qY5iZe9yo+mypTB6pdp4anp90TMCgTOGie+aYXfwg3Vg6mbmq6bugHmug3RSZ3wSp0d0K7Vs4ZueK9uqAH0mj4s9mL++mIcsK8LcB3eUbAG+x0C26//urBKFLDSYa/4GrH8pa/S8a7xerFhN6/Sga7q2rGPyq7JARHjylB5WrIme7Iom7Iqu7Is27Iu+7IwG7N1CgPeaWA2qwL6ebM6iwIaurM++7NAG7RCO7REW7RGe7RIm7RKu7RMezesaATDcaFAEDiRoAT/IbUDeJOWMgEAGMCYv/ChQABVRpCKSIAaLjm1W8sHwzizWBuXRyAK2gK1N6UDnYAXScFBT4SR5bSdNkBpRlA6aEkEslG2nkOJONA530MEibmYSIAKFQCeQZBUdNsgXNsJeJuWFBCPEUAAFtC19oA49VJ+NIBXRoCNehsEu4FARoAPhnsDsxOUqDuaUgsEhJkjXVUDDfI7amULidE5E5A+8fRx81ABtHBaYCsDt1UE70gEzPFhE0ALrVsRnpAAyhMBsIsn09txwSkEXPE9qQYE3UuMhHUDuJBWapEYdYEKXFEJQsEUP8m3NpC8QyCQRkAeR/C4FjC+cXAOeHORbEsD//z7tKwgBAE8CRIADMLZAwWsMbdLA5/AFBhwvkqxvmvBvraQOe/bA/IbBBWZBNebJRukBytpP2cbJ/5JuWPLE8wgumGrWXQLCu4jwejRFAlQDZnDGMPLCYTBwjJAXEaAkv+LAwpCQYpbCYvBw3TwwTxgAR26AMerwQITxDghCi9cHa21GcU7D+xrGBOQGd37xC+wWkYQwkWwIfUQiw3ctD+AwWr8QmzcxnAcx3I8x3Rcx3Z8x3icx3q8x3zcx378x4AcyII8yIRcyEOgTS/wtSvQtUmgyF5gAbMDxitQAQuQwL8Jv4MsChMgyRW8Aphlu1LsBKowDkhsgA0sWi5hyP9IpRR14RQSkD4UEBVduwAZsA8UDAl5A8kUYBipkAGzgwHDUrWbq1yprJi2IAGz3A2/sAD+UQGZyzxAMTvN7MsU8EEuUcMZMAkuoSrJcAHRYg+BA86cm7/J4BJ5UwG+DMwAYAyVXALeHMsAEDi6sAz0QwDJsAznIBTLDM+ga8/FjM4LoM7D3LXRmx+jMDzLRwA5XC8EBAEVzBUfxBTjwMs1nA7oAgETkD0G8EGYlRgYTQ4OTQsYEBQX4LvA2xjFALwOMMrF4BScmQG04BTA4DlaMdJrtQATIA4Q8D54YTzaOA4T4BPzAAFxW7k2bQGq4BvmQMHry8YUEMEPUrxO3Lv/QU0AQT3Dn+A5lkzHlhs/j8sNxnDBXes55WMA1zYMh4FZDuDL/Pk7yyc7m5EYaZUB9gwAxsMMn5C+nTwCEnABFDAPBPC4RP1RmDUPmrEOVy0BTSE5GG0A+yABQc0U2FkX9kAL9HMeib3YwADZoMDUwWsLm7sARyVa6LtWls3G7svHx9fOrNMMCdAbyDXBucuYHa0UIj08o4wWFhnXSuHMXDwYzeAStUPBI7B8F7BvkOw5aFnbxbWhnKATxuDQImAM85A3nm3BSKUT5IQ4xqC+w/3ZnfMAa107pC3butDUQvHGeuyZaeUA1CvcnMvLXGEBJN0WtcDESgEMFsC4NFVV6UHx1GRdyTXs2NyTANdMw8zTIMyRAOKXAGm129Sr2QgEFVyBF4gTFLFjXS5dVjSM0TMcFxRebor9UspHAMWCwZmTC9ig4Nbb2x2e0Wys3nnsmc5MGawGAfLdCpDt2HwNDDje254DDB2YOmVlGH+tFEHhQZJTPMdgC1lckMMIDPaMDwXDmYaxAJPwyRIQFM8bz6e1FplhGFjZQQUj45LD5XG7GKrRE0GB3fiixWvh2Gp9PPsQ42msyjlAC1u9BJ9cA4ot3XiOCGlVwkjQ5zSwb4Ge6Iq+6Ize6I7+6JAe6ZI+6ZRe6ZauHCEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Analysis of WHO 1981 data.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31277=[""].join("\n");
var outline_f30_34_31277=null;
var title_f30_34_31278="CF vit preps fat sol";
var content_f30_34_31278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fat-soluble vitamins preparations for individuals with cystic fibrosis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        SourceCF&reg; (drops, chewables, softgels)",
"       </td>",
"       <td class=\"subtitle1\">",
"        AquADEK&reg; (chewables)",
"       </td>",
"       <td class=\"subtitle1\">",
"        AquADEKs&reg; (drops, softgels)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamax&reg; (drops, chewables)",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Poly-Vi-Sol&reg; (drops)",
"        </p>",
"        <p>",
"         Centrum&reg; (chewable, tablet)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Total Vitamin A (International Units, IU) (Retinol and Beta Carotene)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        <p>",
"         4627 IU/1 mL",
"        </p>",
"        <p>",
"         75 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         5751 IU/1 mL",
"        </p>",
"        <p>",
"         87 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        3170 IU/1 mL as 100 percent retinol palmitate",
"       </td>",
"       <td>",
"        1500 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        <p>",
"         9254 IU/2 mL",
"        </p>",
"        <p>",
"         75 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         11,502 IU/2 mL",
"        </p>",
"        <p>",
"         87 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        6340 IU/2 mL as 100 percent retinol palmitate",
"       </td>",
"       <td>",
"        3000 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        <p>",
"         16,000 IU/1 chewable",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         18,167 IU/2 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         18,167 IU/1 softgel",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         5000 IU/1 chewable",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         3500 IU/1 chewable",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        <p>",
"         32,000 IU/2 softgels",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         36,334 IU/4 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         36,334 IU/2 softgels",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         10,000 IU/2 chewables",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         7000 IU/2 tablets",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        <p>",
"         32,000 IU/2 softgels",
"        </p>",
"        <p>",
"         88 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         36,334 IU/4 chewables",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         36,334 IU/2 softgels",
"        </p>",
"        <p>",
"         92 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         10,000 IU/2 chewables",
"        </p>",
"        <p>",
"         50 percent as beta-carotene",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         7000 IU/2 tablets",
"        </p>",
"        <p>",
"         29 percent as beta-carotene",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin E (International Units, IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        50 IU/1 mL",
"       </td>",
"       <td>",
"        5 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 IU/2 mL",
"       </td>",
"       <td>",
"        10 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        200 IU/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         100 IU/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         150 IU/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        200 IU/1 chewable",
"       </td>",
"       <td>",
"        30 IU/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        400 IU/2 softgels",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        200 IU/4 chewables",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         300 IU/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        400 IU/2 chewables",
"       </td>",
"       <td>",
"        60 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        400 IU/2 softgels",
"       </td>",
"       <td>",
"        200 IU/4 chewables",
"       </td>",
"       <td>",
"        300 IU/2 softgels",
"       </td>",
"       <td>",
"        400 IU/2 chewables",
"       </td>",
"       <td>",
"        60 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin D (International Units, IU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        500 IU/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"       <td>",
"        400 IU/1 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        1000 IU/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"       <td>",
"        800 IU/2 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        1000 IU/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         800 IU/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         800 IU/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        400 IU/1 chewable",
"       </td>",
"       <td>",
"        400 IU/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        2000 IU/2 softgels",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1600 IU/4 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1600 IU/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        800 IU/2 chewables",
"       </td>",
"       <td>",
"        800 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        2000 IU/2 softgels",
"       </td>",
"       <td>",
"        1600 IU/4 chewables",
"       </td>",
"       <td>",
"        1600 IU/2 softgels",
"       </td>",
"       <td>",
"        800 IU/2 chewables",
"       </td>",
"       <td>",
"        800 IU/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamin K (mcg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-12 months",
"       </td>",
"       <td>",
"        400 mcg/1 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        400 mcg/1 mL",
"       </td>",
"       <td>",
"        300 mcg/1 mL",
"       </td>",
"       <td>",
"        0 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 yrs",
"       </td>",
"       <td>",
"        800 mcg/2 mL",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        800 mcg/2 mL",
"       </td>",
"       <td>",
"        600 mcg/2 mL",
"       </td>",
"       <td>",
"        0 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 yrs",
"       </td>",
"       <td>",
"        800 mcg/1 chewable",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         700 mcg/2 chewables",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         For ages 4-10 years:",
"        </p>",
"        <p>",
"         700 mcg/1 softgel",
"        </p>",
"       </td>",
"       <td>",
"        200 mcg/1 chewable",
"       </td>",
"       <td>",
"        10 mcg/1 chewable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-18 yrs",
"       </td>",
"       <td>",
"        1600 mcg/2 softgels",
"       </td>",
"       <td>",
"        1400 mcg/4 chewables",
"       </td>",
"       <td>",
"        <p>",
"         For ages 10 and up:",
"        </p>",
"        <p>",
"         1400 mcg/2 softgels",
"        </p>",
"       </td>",
"       <td>",
"        400 mcg/2 chewables",
"       </td>",
"       <td>",
"        50 mcg/2 tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;18 yrs",
"       </td>",
"       <td>",
"        1600 mcg/2 softgels",
"       </td>",
"       <td>",
"        1400 mcg/4 chewables",
"       </td>",
"       <td>",
"        1400 mcg/2 softgels",
"       </td>",
"       <td>",
"        400 mcg/2 chewables",
"       </td>",
"       <td>",
"        50 mcg/2 tablets",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    AquADEKs&reg; is a registered trademark of Yasoo Health Inc, Vitamax&reg; is a registered trademark of Shear/Kershman Labs. Inc, Poly-Vi-Sol&reg; is a registered trademark of Mead Johnson and Company, Centrum&reg; is a registered trademark of Wyeth Consumer Care.",
"    <div class=\"footnotes\">",
"     * The content of this table was confirmed with each company as of December 2008.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Also contains mixed tocopherols.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: file://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31278=[""].join("\n");
var outline_f30_34_31278=null;
var title_f30_34_31279="Long axis scan aspiration extensor digitorum tenosynovitis";
var content_f30_34_31279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Long axis scan aspiration extensor digitorum tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long axis scan of needle aspiration of extensor digitorum tenosynovitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_34_31279=[""].join("\n");
var outline_f30_34_31279=null;
